06-01-00

Please type a plus sign (+) inside this box → ☒

PTO/SB/05 (2/98)

A

jc811 U.S. PTO 05/31/00

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C F R § 1 53(b))

Attorney Docket No	LUD 5353.7 DIV (10016357)
First Inventor or Application Identifier	Boon et al
Title	ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTON ANTIGEN PRECURSOR MAGE- 6 AND USES THEREOF
Express Mail Label No.	EL227321843US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ *Fee Transmittal Form *(e g , PTO/SB/17)* *(Submit an original and a duplicate for fee processing)*
2. ☒ Specification *(preferred arrangement set forth below)* — *Total Pages* 85
   - Descriptive title of the Invention
   - Cross References to Related Applications
   - Reference of Microfiche Appendix
   - Background of the Invention
   - Brief Summary of the Invention
   - Brief Description of the Drawings *(if filed)*
   - Detailed Description
   - Claim(s)
   - Abstract of the Disclosure
3. ☒ Drawing(s) *(35 U.S C 113)* — *Total Sheets* 16
4. ☒ Oath or Declaration — *Total Pages* 3
   a. ☐ Newly executed (original or copy)
   b. ☒ Copy from a prior application (37 C F.R. § 1 63(d)) *(for continuation/divisional with Box 17 completed)*
   i ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C F R §§ 1 63(d)(2) and 1.33 (b)
5. ☒ Incorporation By Reference *(useable if Box 4b is checked)* The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be a part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

jc834 U.S. PTO 09/583848 05/31/00

6. ☐ Microfiche Computer Program *(Appendix)*
7. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
   a. ☐ Computer Readable Copy
   b. ☒ Paper Copy (identical to computer copy)
   c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C F R §3 73(b) Statement *(when there is an assignee)* ☒ Power of Attorney
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
14. ☐ *Small Entity Statement(s) (PTO/SB/09-12) ☐ Statement filed in prior application, Status is proper and desired
15. ☐ Certified Copy of Priority Document(s)
16. ☐ Other

NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STSTEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

17. **If a CONTINUING APPLICATION,** *check appropriate box, and supply the requisite information below and in a preliminary amendment:*

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/404,026 (9/23/99)

Prior application information: Examiner: Group / Art Unit

18. CORRESPONDENCE ADDRESS

☐ Customer Number or bar code label *(Insert Customer No or Attach bar code label here)* or ☒ Correspondence address below

Name	FULBRIGHT & JAWORSKI LLP				
Address	666 FIFTH AVENUE				
City	NEW YORK	State	NEW YORK	ZIP Code	10103
Country	USA	Telephone	212-318-3000	Fax	212-752-5958

Name (Print/Type)	NORMAN D. HANSON	Registration No (Attorney/Agent)	30,946
Signature		Date	May 30, 2000

VIA EXPRESS MAIL
"Express Mail" mailing label Number EL227321843US
Date of Deposit May 30, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231
FULBRIGHT & JAWORSKI L.L.P.
By: Joan Cerrone

ATTY. DOCKET NO: LUD 5353.7 DIV (10016357)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Boon, et al
Serial No.	:	TO BE ASSIGNED
Filed	:	HEREWITH
For	:	Isolated Nucleic Acid Molecules Coding For Tumor Rejection Antigen Precursor Mage-6 And Uses Thereof
Group Art Unit	:	NOT YET ASSIGNED
Examiner	:	NOT YET ASSIGNED

May 30, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows:

IN THE TITLE

Change "MAGE-3" to -- MAGE-6 -- .

IN THE SPECIFICATION

Page 1, line 6: after "is" add -- a divisional of Serial No.09/404,026, filed September 23, 1999, which is a divisional of Serial No. 08/967,727, filed on November 27, 1997, now U.S. Patent No.6,025,474, which is a divisional of Serial No. 08/037,230, filed March 26, 1993, now U.S. patent No. _____ which --

line 9: after "1991" add -- now U.S. Patent No. 5,342,774 --

Page 44, line 33: change "TRA" to -- TRAP –.

IN THE CLAIMS

CANCEL claims 1-21 without prejudice

ADD claims 22-36 which follow:

Claim 22. An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor, or a fragment thereof, the complementary sequence of which hybridizes, under stringent conditions, to the nucleotide sequence set forth in SEQ ID NO:18

Claim 23. The isolated nucleic acid molecule of claim 22, wherein said isolated nucleic acid molecule is genomic DNA.

Claim 24. The isolated nucleic acid molecule of claim 22, wherein said isolated nucleic acid molecule is cDNA.

Claim 25. The isolated nucleic acid molecule of claim 24, comprising the nucleotide sequence of SEQ ID NO:18.

Claim 26. The isolated nucleic acid molecule of claim 22, comprising mRNA.

Claim 27. An expression vector comprising the isolated nucleic acid molecule of claim 22, operably linked to a promoter.

Claim 28. The expression vector of claim 27, wherein said promoter is an inducible promoter.

Claim 29. An expression vector comprising the isolated nucleic acid molecule of claim 24, operably linked to a promoter.

Claim 30. The expression vector of claim 29, wherein said promoter is inducible.

Claim 31. A host cell transfected or transformed with the isolated nucleic acid molecule of claim 22.

Claim 32. The host cell of claim 31, wherein said cell is a fibroblast.

Claim 33. A host cell transfected or transformed with the isolated nucleic acid of claim 24.

Claim 34. The host cell of claim 31, wherein said host cell is a mammalian cell.

Claim 35. The host cell of claim 33, wherein said host cell is a mammalian cell.

Claim 36. An isolated protein encoded by the isolated nucleic acid molecule of claim 22.

REMARKS

Entry of the foregoing amendment is requested. The changes to the specification are minor. For example, review of page 44 will show that, on line 30, "TRAP fragments" is recited, so the change to line 33 is appropriate.

This application properly claims priority to, inter alia, Serial No. 807,043, filed December 12, 1991. A review of that application will show that the examiner required applicants to elect a species of MAGE, and applicants elected MAGE-1. In the present case, MAGE-4 and 41 are elected. In view of the examiner's action, double patenting does not lie.

Claim 22, and hence all other claims, are supported via, e.g., page 34, lines 24-28 of the specification.

Entry of the foregoing amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By Norman

Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000

ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR MAGE-3 AND USES THEREOF

RELATED APPLICATION

This application is a continuation-in-part of PCT Application PCT/US92/04354 filed on May 22, 1992 designating the United States, which is a continuation-in-part of Serial Number 807,043, filed December 12, 1991, which is a continuation-in-part of Serial Number 764,364, filed September 23, 1991, which is a continuation-in-part of Serial Number 728,838, filed July 9, 1991, which is a continuation-in-part of Serial Number 705,702, filed May 23, 1991, and now abandoned.

FIELD OF THE INVENTION

This invention relates in general to the field of immunogenetics as applied to the study of oncology. More specifically, it relates to the study and analysis of mechanisms by which tumors are recognized by the organism's immune system such as through the presentation of so-called tumor rejection antigens, and the expression of what will be referred to herein as "tumor rejection antigen precursors" or "TRAPs". Most specifically, it refers to nucleic acid molecules coding for one such TRAP, i.e., MAGE-3, which is processed to a tumor rejection antigen or "TRA" presented by HLA-A1 molecules.

BACKGROUND AND PRIOR ART

The study of the recognition or lack of recognition of cancer cells by a host organism has proceeded in many different directions. Understanding of the field presumes some understanding of both basic immunology and oncology.

Early research on mouse tumors revealed that these displayed molecules which led to rejection of tumor cells when transplanted into syngeneic animals. These molecules are "recognized" by T-cells in the recipient animal, and provoke

a cytolytic T-cell response with lysis of the transplanted cells. This evidence was first obtained with tumors induced in vitro by chemical carcinogens, such as methylcholanthrene. The antigens expressed by the tumors and which elicited the T-cell response were found to be different for each tumor. See Prehn, et al., J. Natl. Canc. Inst. 18: 769-778 (1957); Klein et al., Cancer Res. 20: 1561-1572 (1960); Gross, Cancer Res. 3: 326-333 (1943), Basombrio, Cancer Res. 30: 2458-2462 (1970) for general teachings on inducing tumors with chemical carcinogens and differences in cell surface antigens. This class of antigens has come to be known as "tumor specific transplantation antigens" or "TSTAs". Following the observation of the presentation of such antigens when induced by chemical carcinogens, similar results were obtained when tumors were induced in vitro via ultraviolet radiation. See Kripke, J. Natl. Canc. Inst. 53: 333-1336 (1974).

While T-cell mediated immune responses were observed for the types of tumor described supra, spontaneous tumors were thought to be generally non-immunogenic. These were therefore believed not to present antigens which provoked a response to the tumor in the tumor carrying subject. See Hewitt, et al., Brit. J. Cancer 33: 241-259 (1976).

The family of tum^- antigen presenting cell lines are immunogenic variants obtained by mutagenesis of mouse tumor cells or cell lines, as described by Boon et al., J. Exp. Med. 152: 1184-1193 (1980), the disclosure of which is incorporated by reference. To elaborate, tum^- antigens are obtained by mutating tumor cells which do not generate an immune response in syngeneic mice and will form tumors (i.e., "tum^+" cells). When these tum^+ cells are mutagenized, they are rejected by syngeneic mice, and fail to form tumors (thus "tum^-"). See Boon et al., Proc. Natl. Acad. Sci. USA 74: 272 (1977), the disclosure of which is incorporated by reference. Many tumor types have been shown to exhibit this phenomenon. See, e.g., Frost et al., Cancer Res. 43: 125 (1983).

It appears that tum^- variants fail to form progressive tumors because they elicit an immune rejection process. The

evidence in favor of this hypothesis includes the ability of "tum$^-$" variants of tumors, i.e., those which do not normally form tumors, to do so in mice with immune systems suppressed by sublethal irradiation, Van Pel et al., Proc. Natl, Acad. Sci. USA 76: 5282-5285 (1979); and the observation that intraperitoneally injected tum$^-$ cells of mastocytoma P815 multiply exponentially for 12-15 days, and then are eliminated in only a few days in the midst of an influx of lymphocytes and macrophages (Uyttenhove et al., J. Exp. Med. 152: 1175-1183 (1980)). Further evidence includes the observation that mice acquire an immune memory which permits them to resist subsequent challenge to the same tum$^-$ variant, even when immunosuppressive amounts of radiation are administered with the following challenge of cells (Boon et al., Proc. Natl, Acad. Sci. USA 74: 272-275 (1977); Van Pel et al., supra; Uyttenhove et al., supra). Later research found that when spontaneous tumors were subjected to mutagenesis, immunogenic variants were produced which did generate a response. Indeed, these variants were able to elicit an immune protective response against the original tumor. See Van Pel et al., J. Exp. Med. 157: 1992-2001 (1983). Thus, it has been shown that it is possible to elicit presentation of a so-called "tumor rejection antigen" in a tumor which is a target for a syngeneic rejection response. Similar results have been obtained when foreign genes have been transfected into spontaneous tumors. See Fearson et al., Cancer Res. 48: 2975-1980 (1988) in this regard.

A class of antigens has been recognized which are presented on the surface of tumor cells and are recognized by cytotoxic T cells, leading to lysis. This class of antigens will be referred to as "tumor rejection antigens" or "TRAs" hereafter. TRAs may or may not elicit antibody responses. The extent to which these antigens have been studied, has been via cytolytic T cell characterization studies, in vitro i.e., the study of the identification of the antigen by a particular cytolytic T cell ("CTL" hereafter) subset. The subset proliferates upon recognition of the presented tumor rejection

antigen, and the cells presenting the antigen are lysed. Characterization studies have identified CTL clones which specifically lyse cells expressing the antigens. Examples of this work may be found in Levy et al., Adv. Cancer Res. 24: 1-59 (1977); Boon et al., J. Exp. Med. 152: 1184-1193 (1980); Brunner et al., J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982); Palladino et al., Canc. Res. 47: 5074-5079 (1987). This type of analysis is required for other types of antigens recognized by CTLs, including minor histocompatibility antigens, the male specific H-Y antigens, and a class of antigens, referred to as "tum-" antigens, and discussed herein.

A tumor exemplary of the subject matter described supra is known as P815. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988); Szikora et al., EMBO J 9: 1041-1050 (1990), and Sibille et al., J. Exp. Med. 172: 35-45 (1990), the disclosures of which are incorporated by reference. The P815 tumor is a mastocytoma, induced in a DBA/2 mouse with methylcholanthrene and cultured as both an in vitro tumor and a cell line. The P815 line has generated many tum^- variants following mutagenesis, including variants referred to as P91A (DePlaen, supra), 35B (Szikora, supra), and P198 (Sibille, supra). In contrast to tumor rejection antigens - and this is a key distinction - the tum^- antigens are only present after the tumor cells are mutagenized. Tumor rejection antigens are present on cells of a given tumor without mutagenesis. Hence, with reference to the literature, a cell line can be tum^+, such as the line referred to as "P1", and can be provoked to produce tum^- variants. Since the tum^- phenotype differs from that of the parent cell line, one expects a difference in the DNA of tum^- cell lines as compared to their tum^+ parental lines, and this difference can be exploited to locate the gene of interest in tum^- cells. As a result, it was found that genes of tum^- variants such as P91A, 35B and P198 differ from their normal alleles by point mutations in the coding regions of the gene. See Szikora and Sibille, supra, and Lurquin et

al., Cell 58: 293-303 (1989). This has proved not to be the case with the TRAs of this invention. These papers also demonstrated that peptides derived from the tum^- antigen are presented by the L^d molecule for recognition by CTLs. P91A is presented by L^d, P35 by D^d and P198 by K^d.

Prior patent applications PCT/US92/04354, U.S. Serial No. 807,043; 764,364; 728,838 and 707,702, all of which are incorporated by reference, describe inventions involving, inter alia, genes and other nucleic acid molecules which code for various TRAPs, which are in turn processed to tumor rejection antigen, or "TRAs".

The genes are useful as a source for the isolated and purified tumor rejection antigen precursor and the TRA themselves, either of which can be used as an agent for treating the cancer for which the antigen is a "marker", as well as in various diagnostic and surveillance approaches to oncology, discussed infra. It is known, for example, that tum^- cells can be used to generate CTLs which lyse cells presenting different tum^- antigens as well as tum^+ cells. See, e.g., Maryanski et al., Eur. J. Immunol 12: 401 (1982); and Van den Eynde et al., Modern Trends in Leukemia IX (June 1990), the disclosures of which are incorporated by reference. The tumor rejection antigen precursor may be expressed in cells transfected by the gene, and then used to generate an immune response against a tumor of interest.

In the parallel case of human neoplasms, it has been observed that autologous mixed lymphocyte-tumor cell cultures ("MLTC" hereafter) frequently generate responder lymphocytes which lyse autologous tumor cells and do not lyse natural killer targets, autologous EBV-transformed B cells, or autologous fibroblasts (see Anichini et al., Immunol. Today 8: 385-389 (1987)). This response has been particularly well studied for melanomas, and MLTC have been carried out either with peripheral blood cells or with tumor infiltrating lymphocytes. Examples of the literature in this area including Knuth et al., Proc. Natl. Acad. Sci. USA 86: 2804-2802 (1984); Mukherji et al., J. Exp. Med. 158: 240 (1983);

Hérin et all, Int. J. Canc. 39: 390-396 (1987); Topalian et al, J. Clin. Oncol 6: 839-853 (1988). Stable cytotoxic T cell clones ("CTLs" hereafter) have been derived from MLTC responder cells, and these clones are specific for the tumor cells. See Mukherji et al., supra, Hérin et all, supra, Knuth et al., supra. The antigens recognized on tumor cells by these autologous CTLs do not appear to represent a cultural artifact, since they are found on fresh tumor cells. Topalian et al., supra; Degiovanni et al., Eur. J. Immunol. 20: 1865-1868 (1990). These observations, coupled with the techniques used herein to isolate the genes for specific murine tumor rejection antigen precursors, have led to the isolation of nucleic acid sequences coding for tumor rejection antigen precursors of TRAs presented on human tumors. It is now possible to isolate the nucleic acid sequences which code for tumor rejection antigen precursors, including, but not being limited to those most characteristic of a particular tumor, with ramifications that are described infra.

Additional work has focused upon the presentation of TRAs by the class of molecules known as human leukocyte antigens, or "HLAs". This work has resulted in several unexpected discoveries regarding the field. Specifically in U.S. patent application Serial Number 938,334, the disclosure of which is incorporated by reference, nonapeptides are taught which are presented by the HLA-A1 molecule. The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind one HLA molecule, but not others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.

In U.S. Patent Application Serial Number 008,446, filed January 22, 1993 and incorporated by reference, the fact that the MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-C10-molecules. The disclosure shows that a given TRAP can yield a plurality of TRAs.

In U.S. Patent Application Serial Number 994,928, filed December 22, 1992, and incorporated by reference herein, tyrosinase is described as a tumor rejection antigen precursor. This reference discloses that a molecule which is produced by some normal cells (e.g., melanocytes), is processed in tumor cells to yield a tumor rejection antigen that is presented by HLA-A2 molecules.

It was mentioned, supra, that different individuals possess different HLA types. It has also been found that the expression of particular MAGE genes is not always linked to particular disorders, or individuals of particular HLA types. Thus, one cannot state, e.g., that all melanoma patients will express MAGE-1 TRAP nor could one say categorically that MAGE-1 expression is limited to melanoma patients of type HLA-A1. Further, one cannot state that only one type of TRAP is expressed in individuals of a particular HLA type. No rules or guidelines can be pointed to which correlate any of these factors.

Thus, it is not expected that a second TRAP is processed to a TRAP which is presented by HLA-A1 molecules. It has now been found that in addition to MAGE-1, a TRA derived from MAGE-3 TRAP is presented by HLA-A1 molecules. This is shown in examples 37-40, which follow, together with a discussion of the ramifications of this discovery.

These and various other aspects of the invention are elaborated upon in the disclosure which follows.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts detection of transfectants expressing antigen P815A.

Figure 2 shows the sensitivity of clones P1.HTR, PO.HTR, genomic transfectant P1A.T2 and cosmid transfectant P1A.TC3.1

to lysis by various CTLs, as determined by chromium release assays.

Figure 3 is a restriction map of cosmid C1A.3.1.

Figure 4 shows Northern Blot analysis of expression of gene P1A.

Figure 5 sets forth the structure of gene P1A with its restriction sites.

Figure 6 shows the results obtained when cells were transfected with the gene from P1A, either isolated from P815 or normal cells and then tested with CTL lysis.

Figure 7 shows lytic studies using mast cell line L138. 8A.

Figure 8 is a map of subfragments of the 2.4 kb antigen E fragment sequence which also express the antigen.

Figure 9 shows homology of sections of exon 3 from genes mage 1, 2 and 3.

Figure 10 shows the result of Northern blots for MAGE genes on various tissues.

Figure 11 presents the data of Figure 13 in table form. Figure 12 shows Southern Blot experiments using the various human melanoma cell lines employed in this application.

Figure 13 is a generalized schematic of the expression of MAGE 1, 2 and 3 genes by tumor and normal tissues.

Figure 14 shows results from a chromium release assay using CTL clone 20/38 on various cell lines.

Figure 15 presents the result of assays undertaken to determine antigenic specificity of CTL clone 20/38.

Figure 16 shows the results obtained when a TNF release assay was carried out on various transfected cells.

BRIEF DESCRIPTION OF SEQUENCES

SEQ ID NO: 1 is cDNA for part of gene P1A.

SEQ ID NO: 2 presents coding region of cDNA for gene P1A.

SEQ ID NO: 3 shows non coding DNA for P1A cDNA which is 3' to the coding region of SEQ ID NO: 2.

SEQ ID NO: 4 is the entire sequence of cDNA for P1A.

SEQ ID NO: 5 is the genomic DNA sequence for P1A.

SEQ ID NO: 6 shows the amino acid sequence for the

antigenic peptides for P1A TRA. The sequence is for cells which are A^+ B^+, i.e., express both the A and B antigens.

SEQ ID NO: 7 is a nucleic acid sequence coding for antigen E.

SEQ ID NO: 8 is a nucleic acid sequence coding for MAGE-1.

SEQ ID NO: 9 is the gene for MAGE-2.

SEQ ID NO: 10 is the gene for MAGE-21.

SEQ ID NO: 11 is cDNA for MAGE-3.

SEQ ID NO: 12 is the gene for MAGE-31.

SEQ ID NO: 13 is the gene for MAGE-4.

SEQ ID NO: 14 is the gene for MAGE-41.

SEQ ID NO: 15 is cDNA for MAGE-4.

SEQ ID NO: 16 is cDNA for MAGE-5.

SEQ ID NO: 17 is genomic DNA for MAGE-51.

SEQ ID NO: 18 is cDNA for MAGE-6.

SEQ ID NO: 19 is genomic DNA for MAGE-7.

SEQ ID NO: 20 is genomic DNA for MAGE-8.

SEQ ID NO: 21 is genomic DNA for MAGE-9.

SEQ ID NO: 22 is genomic DNA for MAGE-10.

SEQ ID NO: 23 is genomic DNA for MAGE-11.

SEQ ID NO: 24 is genomic DNA for smage-I.

SEQ ID NO: 25 is genomic DNA for smage-II.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Many different "MAGE" genes have been identified, as will be seen from the sequences which follow the application. The protocols described in the following examples were used to isolate these genes and cDNA sequences.

"MAGE" as used herein refers to a nucleic acid sequence isolated from human cells. The acronym "smage" is used to describe sequences of murine origin.

When "TRAP" or "TRAs" are discussed herein as being specific to a tumor type, this means that the molecule under consideration is associated with that type of tumor, although not necessarily to the exclusion of other tumor types.

Example 1

In order to identify and isolate the gene coding for

antigen P815A, gene transfection was used. This approach requires both a source of the gene, and a recipient cell line. Highly transfectable cell line P1.HTR was the starting material for the recipient, but it could not be used without further treatment, as it presents "antigen A", one of four recognized P815 tumor antigens. See Van Pel et al., Molecular Genetics 11: 467-475 (1985). Thus, screening experiments were carried out to isolate cell lines which did not express the antigen and which nonetheless possessed P1.HTR's desirable qualities.

To do this, P1.HTR was screened with CTLs which were specific for each of tumor antigens A, B, C and D. Such CTLs are described by Uyttenhove et al., J. Exp. Med. 157: 1040-1052 (1983).

To carry out the selection, 10^6 cells of P1.HTR were mixed with 2-4x10^6 cells of the CTL clone in a round bottom tube in 2 ml of medium, and centrifuged for three minutes at 150xg. After four hours at 37°C, the cells were washed and resuspended in 10 ml of medium, following Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982). Additional information on the CTL assay and screening protocol, in general may be found in Boon et al., J. Exp. Med. 152: 1184-1193 (1980), and Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982), the disclosure of which are incorporated by reference.

When these selections were carried out, a cell line variant was found which expressed neither antigen A or B. Additional selections with CTLs specific for antigen C then yielded a variant which also lacked antigen C. Please see figure 2 for a summary of the results of these screenings. The variant PO.HTR is negative for antigens A, B and C, and was therefore chosen for the transfection experiments.

The cell line PO.HTR has been deposited in accordance with the Budapest Treaty at the Institute Pasteur Collection Nationale De Cultures De Microorganismes, 28, Rue de Docteur Roux, 75724 Paris France, and has accession number I-1117.

This methodology is adaptable to secure other cell lines which are variants of a cell type which normally presents at

least one of the four recognized P815 tumor antigens, i.e., antigens A, B, C and D, where the variants present none of antigens A, B and C. P1.HTR is a mastocytoma cell line, so it will be seen that the protocol enables the isolation of biologically pure mastocytoma cell lines which express none of P815 antigens A, B and C, but which are highly transfectable. Other tumor types may also be screened in this fashion to secure desired, biologically pure cell lines. The resulting cell lines should be at least as transfectable with foreign DNA as is P1.HTR, and should be selected so as to not express a specific antigen.

Example 2

Previous work reported by DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988) the disclosure of which is incorporated by reference herein had shown the efficacy of using cosmid library transfection to recover genes coding for tum^- antigens.

Selective plasmid and genomic DNA of P1.HTR were prepared, following Wölfel et al., Immunogenetics 26: 178-187 (1987). The transfection procedure followed Corsaro et al., Somatic Cell Molec. Genet 7: 603-616 (1981), with some modification. Briefly, 60 μg of cellular DNA and 3 μg of DNA of plasmid pHMR272, described by Bernard et al., Exp. Cell. Biol. 158: 237-243 (1985) were mixed. This plasmid confers hygromycin resistance upon recipient cells,
and therefore provides a convenient way to screen for transfectants. The mixed DNA was combined with 940 ul of 1 mM Tris-HCl (pH 7.5), 0.1 mM EDTA; and 310 ul 1M $CaCl_2$. The solution was added slowly, and under constant agitation to 1.25 ml of 50 mM Hepes, 280 mM NaCl, 1.5 mM Na_2HPO_4, adjusted to pH 7.1 with NaOH. Calcium phosphate - DNA precipitates were allowed to form for 30-45 minutes at room temperature. Following this, fifteen groups of PO.HTR cells ($5x10^6$) per group were centrifuged for 10 minutes at 400 g. Supernatants were removed, and pellets were resuspended directly into the medium containing the DNA precipitates. This mixture was incubated for 20 minutes at 37°C, after which it was added to

an 80 cm^2 tissue culture flask containing 22.5 ml DMEM, supplemented with 10% fetal calf serum. After 24 hours, medium was replaced. Forty-eight hours after transfection, cells were collected and counted. Transfected cells were selected in mass culture using culture medium supplemented with hygromycin B (350 ug/ml). This treatment selected cells for hygromycin resistance.

For each group, two flasks were prepared, each containing $8x10^6$ cells in 40 ml of medium. In order to estimate the number of transfectants, $1x10^6$ cells from each group were plated in 5 ml DMEM with 10% fetal calf serum (FCS), 0.4% bactoagar, and 300 ug/ml hygromycin B. The colonies were then counted 12 days later. Two independent determinations were carried out and the average taken. This was multiplied by 5 to estimate the number of transfectants in the corresponding group. Correction had to be made for the cloning efficiency of P815 cells, known to be about 0.3.

Example 3

Eight days after transfection as described in example 2, supra, antibiotic resistant transfectants were separated from dead cells, using density centrifugation with Ficoll-Paque. These cells were maintained in non-selective medium for 1 or 2 days. The cells were plated in 96 well microplates (round bottom), at 30 cells/microwell in 200 ul of culture medium. Anywhere from 100-400 microwells were prepared, depending on the number of transfectants prepared. Agar colony tests gave estimates of 500-3000. After 5 days, the wells contained about $6x10^4$ cells and replicate plates were prepared by transferring 1/10 of the wells to microplates which were then incubated at 30°C. One day later, master plates were centrifuged, medium removed, and 750 CTLs against P815 antigen A (CTL-P1:5) were added to each well together with 10^6 irradiated syngeneic feeder spleen cells in CTL culture medium containing 40 U/ml recombinant human IL-2, and HAT medium to kill stimulator cells. Six days later, plates were examined visually to identify wells where CTLs had proliferated. Where plates showed proliferating microcultures, aliquots of 100 ul

of the wells were transferred to another plate containing ^{51}Cr labeled P1.HTR target cells ($2x10^3$ - $4x10^3$ per well), and chromium release was measured after 4 hours. Replicate microcultures corresponding to those showing high CTL activity were expanded and cloned by limited dilution in DMEM with 10% FCS. Five days later, about 200 clones were collected and screened with the CTL.P1:5 cell line, described supra, in a visual lysis assay. See figure 1A for these results.

In these experiments, three of the fifteen groups of transfectants yielded a few positive microcultures. These microcultures were tested for lytic activity against P1.HTR, as described supra. Most of the microcultures where proliferation was observed showed lytic activity. This activity was well above background, as shown in figure 1B. This figure summarizes data wherein two groups of cells (groups "5" and "14"), 400 and 300 microwells were seeded with 30 hygromycin resistant transfected cells. Amplification and duplication of the microcultures was followed by addition of anti-A CTL P1:5. Six days later, lytic activity against P1.HTR was tested. In the figure, each point represents lytic activity of a single microculture.

Duplicate microcultures corresponding to several positive wells were subcloned, and more than 1% of the subclones were found to be lysed by anti-A CTL. Thus, three independent transfectants expressing P815A were obtained from 33,000 hygromycin resistant transfectants. One of these lines, referred to hereafter as P1A.T2 was tested further.

The relevant antigen profile of P1A.T2 is shown in figure 2, this being obtained via anti-CTL assays of the type described supra.

Example 4

The CTL assays carried out for P1A.T2 demonstrated that it presented antigen A ("P815A"), and therefore had received the gene from P1.HTR. To that end, this cell line was used as a source for the gene for the antigen precursor in the following experiments.

Prior work had shown that genes coding for tum$^-$ antigens

could be recovered directly from transfectants obtained with a cosmid library. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988). This procedure was followed for recovery of the P815 gene.

Total genomic DNA of P1A.T2 was partially digested with restriction endonuclease Sau 3A1, and fractionated by NaCl density gradient ultracentrifugation to enrich for 35-50 kb DNA fragments, following Grosveld et al., Gene 10: 6715-6732 (1982). These fragments were ligated to cosmid arms of C2RB, described by Bates et al., Gene 26: 137-146 (1983), the disclosure of which is incorporated by reference. These cosmid arms had been obtained by cleavage with SmaI and treatment with calf intestinal phosphatase, followed by digestion with BamHI. Ligated DNA was packaged into lambda phage components, and titrated on E. coli ED 8767, following Grosveld et al., supra. Approximately $9x10^5$ ampicillin resistant colonies were obtained per microgram of DNA insert.

The cosmid groups were amplified by mixing 30,000 independent cosmids with 2 ml of ED 8767 in 10 mM $MgCl_2$, incubated 20 minutes at 37°C, diluted with 20 ml of Luria Bertani ("LB") medium, followed by incubation for one hour. This suspension was titrated and used to inoculate 1 liter of LB medium in the presence of ampicillin (50 ug/ml). At a bacterial concentration of $2x10^8$ cells/ml (OD_{600}=0.8), a 10 ml aliquot was frozen, and 200 ug/ml chloramphenicol was added to the culture for overnight incubation. Total cosmid DNA was isolated by alkaline lysis procedure, and purified on CsCl gradient.

In these experiments, a library of 650,000 cosmids was prepared. The amplification protocol involved the use of 21 groups of approximately 30,000 cosmids.

Example 5

Using the twenty-one groups of cosmids alluded to supra, (60 ug) and 4 ug of pHMR272, described supra, groups of $5x10^6$ PO.HTR cells were used as transfectant hosts. Transfection was carried out in the same manner as described in the preceding experiments. An average of 3000 transfectants per

group were tested for antigen presentation, again using CTL assays as described. One group of cosmids repeatedly yielded positive transfectants, at a frequency of about 1/5,000 drug resistant transfectants. The transfectants, as with P1A.T2, also showed expression of both antigen A and B. The pattern of expression of transfectant P1A.TC3.1 is shown in figure 2.

Example 6

As indicated in Example 5, supra, three independent cosmid transfected cells presenting P815A antigen were isolated. The DNA of these transfectants was isolated and packaged directly with lambda phage extracts, following DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988). The resulting product was titrated on E. coli ED 8767 with ampicillin selection, as in Example 5. Similarly, amplification of the cosmids and transfection followed Example 5, again using PO.HTR.

High frequencies of transfection were observed, as described in Table 1, which follows:

Table 1. Transfer of the expression of antigen P815A by cosmids obtained by direct packaging

Transfectant obtained with the cosmid library	No. of cosmids obtained by direct packaging of 0.5 μg of DNA	No. of transfectants expressing P815A / no. of HmB^r transfectants
TC3.1	32	87/192
TC3.2	32000	49/384
TC3.3	44	25/72

The cosmids were analyzed with restriction enzymes and it was found that directly packaged transfectant P1A.TC3.1 contained 32 cosmids, 7 of which were different. Each of these 7 cosmids was transfected into PO.HTR, in the manner described supra, and again, following the protocols described above, transfectants were studied for presentation of P815A.

Four of the cosmid transfectants showed P815A presentation and, as with all experiments described herein, P815B was co-expressed.

Of the four cosmids showing presentation of the two antigens, cosmid C1A.3.1 was only 16.7 kilobases long, and was selected for further analysis as described infra.

The cosmid C1A.3.1 was subjected to restriction endonuclease analysis, yielding the map shown in Figure 3.

All EcoRI fragments were transfected, again using the above described protocols, and only the 7.4 kilobase fragment produced a transfectant that anti-A CTLs could lyse. Similar experiments were carried out on the PstI fragments, and only a 4.1 kb fragment fully contained within the 7.4 kb EcoRI fragment produced lysable transfectants.

This fragment (i.e., the 4.1 kb PstI fragment), was digested with SmaI, giving a 2.3 kb fragment which also yielded host cells presenting antigens A and B after transfection. Finally, a fragment 900 bases long, secured with SmaI/XbaI, also transferred expression of the precursors of these two antigens, i.e., the transfected host cell presented both antigen A and antigen B.

Example 7

The 900 base fragment described above was used as a probe to detect the expression of the P815A gene in parent cell line P1.HTR. To accomplish this, total cellular RNA was first isolated using the guanidine-isothiocyanate procedure of Davis et al., Basic Methods In Molecular Biology (Elseview Science Publishing Co, New York) (1986). The same reference was the source of the method used to isolate and purify polyA$^+$ mRNA using oligodT cellulose column chromatography.

Samples were then subjected to Northern Blot analysis. RNA samples were fractionated on 1% agarose gels containing 0.66 M formaldehyde. The gels were treated with 10xSSC (SSC: 0.15 M NaCl; 0.015 M sodium citrate, pH 7.0) for 30 minutes before overnight blotting on nitrocellulose membranes. These were baked for two hours at 80°C, after which the membranes

were prehybridized for 15 minutes at 60°C in a solution containing 10% dextran sulfate, 1% SDS and 1M NaCl. Hybridization was then carried out using denatured probe (the 900 base fragment), together with 100 ug/ml salmon sperm DNA.

When this protocol was carried out using P1.HTR poly A^+ RNA, a band of 1.2 kb and two fainter bands were identified, as shown in Figure 4, lane 1 (6 ug of the RNA).

The same probe was used to screen a cDNA library, prepared from poly-A^+ RNA from the cell line. This yielded a clone with a 1kb insert, suggesting a missing 5' end. The Northern blots for the cDNA are not shown.

Hybridization experiments in each case were carried out overnight at 60°C. The blots were washed twice at room temperature with 2xSSC and twice at 60°C with 2xSSC supplemented with 1% SDS.

The foregoing experiments delineated the DNA expressing the P815A antigen precursor sufficiently to allow sequencing, using the well known Sanger dideoxy chain termination method. This was carried out on clones generated using a variety of restriction endonucleases and by specific priming with synthetic oligonucleotide primers. The results for exons of the gene are set forth in sequence id no: 4.

Example 8

The Northern analysis described supra suggested that the 5' end of the cDNA was missing. To obtain this sequence, cDNA was prepared from P1.HTR RNA using a primer corresponding to positions 320-303. The sequence was then amplified using the polymerase chain reaction using a 3' primer corresponding to positions 286-266 and a 5' primer described by Frohman et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002 (1988). A band of the expected size (270 bases) was found, which hybridized to the 900 bp SmaI/XbaI fragment described supra on a Southern blot. Following cloning into m13tg 130 λ tg 131, the small, 270 bp fragment was sequenced. The sequence is shown in sequence id no: 1.

Example 9

Following the procurement of the sequences described in Examples 7 and 8 and depicted in seq id no: 4, a 5.7 kb region of cosmid C1A.3.1 was sequenced. This fragment was known to contain the 900 base fragment which expressed P815A in transfectants. This experiment permitted delineation of introns and exons, since the cosmid is genomic in origin.

The delineated structure of the gene is shown in figure 5. Together with seq id no: 4, these data show that the gene for the antigen precursor, referred to as "P1A" hereafter, is approximately 5 kilobases long and contains 3 exons. An ORF for a protein of 224 amino acids starts in exon 1, ending in exon 2. The 900 base pair fragment which transfers expression of precursors for antigens A and B only contains exon 1. The promoter region contains a CAAT box, as indicated in seq. id no: 1, and an enhancer sequence. This latter feature has been observed in promoters of most MHC class I genes, as observed by Geraghty et al., J. Exp. Med 171: 1-18 (1990); Kimura et al., Cell 44: 261-272 (1986).

A computer homology search was carried out, using program FASTA with K-triple parameters of 3 and 6, as suggested by Lipman et al., Science 227: 1435-1441 (1985), and using Genbank database release 65 (October 1990). No homology was found except for a stretch of 95 bases corresponding to part of an acid region coded by exon 1 (positions 524-618), which is similar to sequences coding for acidic regions in mouse nucleolar protein NO38/B23, as described by Bourbon et al., Mol. Biol. 200: 627-638 (1988), and Schmidt-Zachmann et al., Chromosoma 96: 417-426 (1988). Fifty six of 95 bases were identical. In order to test whether these homologies were the reason for cross hybridizing, experiments were carried out using a mouse spleen cDNA library screened with the 900 base fragment. cDNA clones corresponding closely to the sizes of the cross hybridizing bands were obtained. These were partially sequenced, and the 2.6 kb cDNA was found to correspond exactly to reported cDNA sequence of mouse nucleolin, while the 1.5 kb cDNA corresponded to mouse nucleolar protein NO38/B23.

Analysis of the nucleotide sequence of the gene, referred to as "P1A" hereafter, suggests that its coded product has a molecular mass of 25 kd. Analysis of the sequence id no: 4 shows a potential nuclear targeting signal at residues 5-9 (Dingwall et al., Ann. Rev. Cell Biol. 2: 367-390 (1986)), as well as a large acidic domain at positions 83-118. As indicated supra, this contains the region of homology between P1A and the two nucleolar proteins. A putative phosphorylation site can be found at position 125 (serine). Also, a second acidic domain is found close to the C-terminus as an uninterrupted stretch of 14 glutamate residues. A similar C-terminal structure has been found by Kessel et al. Proc. Natl. Acad. Sci. USA 84: 5306-5310 (1987), in a murine homeodomain protein having nuclear localization.

In studies comparing the sequence of gene P1A to the sequences for P91A, 35B and P198, no similarities were found, showing that P1A is indicative of a different class of genes and antigens.

Example 10

With the P1A probe and sequence in hand, investigations were carried out to determine whether the gene present in normal tissue was identical to that expressed by the tumor. To do this, phage libraries were prepared, using lambda zapII 10 and genomic DNA of DBA2 murine kidney cells. P1A was used as a probe. Hybridization conditions were as described supra, and a hybridizing clone was found. The clone contained exons one and two of the P1A gene, and corresponded to positions -0.7 to 3.8 of figure 5. Following localization of this sequence, PCR amplification was carried out to obtain the sequence corresponding to 3.8 to 4.5 of figure 5.

Sequence analysis was carried out, and no differences were found between the gene from normal kidneys and the P1A gene as obtained from the P815 tumor cells.

In further experiments, the gene as found in DBA/2 kidney cells was transfected into PO.HTR, as described supra. These experiments, presented pictorially in figure 7, showed that antigens A and B were expressed as efficiently by the kidney

gene isolated from normal kidney cells as with the P1A gene isolated from normal kidney cells.

These experiments lead to the conclusion that the gene coding for the tumor rejection antigen precursor is a gene that does not result from a mutation; rather, it would appear that the gene is the same as one present in normal cells, but is not expressed therein. The ramifications of this finding are important, and are discussed infra.

In studies not elaborated upon herein, it was found that variants of the gene were available. Some cells were "$P1A^{-}B^{+}$", rather than the normal "P1A". The only difference between these is a point mutation in exon 1, with the 18th triplet coding for Ala in the variant instead of Val.

Example 11

Additional experiments were carried out with other cell types. Following the protocols described for Northern blot hybridizations supra, RNA of normal liver and spleen cells was tested to determine if a transcript of the P1A gene could be found. The Northern blot data are presented in figure 4 and, as can be seen, there is no evidence of expression.

The murine P815 cell line from which P1A was isolated is a mastocytoma. Therefore, mast cell lines were studied to determine if they expressed the gene. Mast cell line MC/9, described by Nabel et al., Cell 23: 19-28 (1981), and short term cultures of bone marrow derived mast cells were tested in the manner described supra (Northern blotting), but no transcript was found. In contrast when a Balb/C derived IL-3 dependent cell line L138.8A (Hültner et al., J. Immunol. 142: 3440-3446 (1989)) was tested, a strong signal was found. The mast cell work is shown in figure 4.

It is known that both BALB/C and DBA/2 mice share $H\text{-}2^{d}$ haplotype, and thus it was possible to test sensitivity to lysis using the CTLs described supra. Figure 8 shows these results, which essentially prove that anti-A and anti-B CTLs lysed the cells strongly, whereas anti-C and anti-D lines did not.

Further tests were carried out on other murine tumor cell

lines, i.e., teratocarcinoma cell line PCC4 (Boon et al., Proc. Natl. Acad. Sci. USA 74: 272-275 (1977), and leukemias LEC and WEH1-3B. Expression could not be detected in any of these samples.

Example 12

The actual presentation of the P1A antigen by MHC molecules was of interest. To test this, cosmid C1A.3.1 was transfected into fibroblast cell line DAP, which shows phenotype H-2^k. The cell lines were transfected with genes expressing one of the K^d, D^d, and L^d antigen. Following transfection with both the cosmid and the MHC gene, lysis with CTLs was studied, again as described supra. These studies, summarized in Table 2, show that L^d is required for presentation of the P1A antigens A and B.

Table 2. H-2-restriction of antigens P815A and P815B

Recipient cell*	No. of clones lysed by the CTL/ no. of HmB^r clones*	
	CTL anti-A	CTL anti-B
DAP (H-2^k)	0/208	0/194
DAP + K^d	0/165	0/162
DAP + D^d	0/157	0/129
DAP + L^d	25/33	15/20

*Cosmid C1A.3.1 containing the entire P1A gene was transfected in DAP cells previously transfected with H-2^d class I genes as indicated.

*Independent drug-resistant colonies were tested for lysis by anti-A or anti-B CTL in a visual assay.

The observation that one may associate presentation of a tumor rejection antigen with a particular MHC molecule was confirmed in experiments with human cells and HLA molecules, as elaborated upon infra.

Example 13

Using the sequence of the P1A gene as well as the amino acid sequence derivable therefrom, antigenic peptides which were A^+ B^+ (i.e., characteristic of cells which express both the A and B antigens), and those which are A^-B^+ were identified. The peptide is presented in Figure 10. This peptide when administered to samples of PO.HTR cells in the presence of CTL cell lines specific to cells presenting it, led to lysis of the PO.HTR cells, lending support to the view that peptides based on the product expressed by the gene can be used as vaccines.

Example 14

The human melanoma cell line referred to hereafter as MZ2-MEL is not a clonal cell line. It expresses four stable antigens recognized by autologous CTLs, known as antigens "D, E, F, and A". In addition, two other antigens "B" and "C" are expressed by some sublines of the tumor. CTL clones specific for these six antigens are described by Van den Eynde et al., Int. J. Canc. 44: 634-640 (1989). Among the recognized subclones of MZ2-MEL are MEL.43, MEL3.0 and MEL3.1. (Van den Eynde et al., supra). Cell line MEL3.1 expresses antigen E, as determined by CTL studies as described for P815 variants, supra, so it was chosen as a source for the nucleic acid sequence expressing the antigen precursor.

In isolating the pertinent nucleic acid sequence for a tumor rejection antigen precursor, the techniques developed supra, showed that a recipient cell is needed which fulfills two criteria: (i) the recipient cell must not express the TRAP of interest under normal conditions, and (ii) it must express the relevant class I HLA molecule. Also, the recipient cell must have a high transfection frequency, i.e., it must be a "good" recipient.

In order to secure such a cell line, the clonal subline

ME3.1 was subjected to repeated selection with anti-E CTL 82/30 as described by Van den Eynde, supra. The repeated cycles of selection led to isolation of subclone MZ2-MEL-2.2 isc E^-. This subclone is also $HPRT^-$, (i.e., sensitive to HAT medium: 10^{-4} M hypoxanthine, 3.8×10^{-7} aminopterine, 1.6×10^{-5} M 2-deoxythymidine). The subclone is referred to as "MEL-2.2" for simplicity hereafter.

Example 15

The genomic DNA of MEL3.0 was prepared following Wölfel et al., Immunogenetics 26: 178-187 (1987), the disclosure of which is incorporated by reference. The plasmid pSVtkneoß, as described by Nicolas et al., Cold Spring Harb., Conf. Cell Prolif. 10: 469-485 (1983) confers geneticin resistance, so it can be used as a marker for cotransfection, as it was in this experiment.

Following a procedure similar but not identical to that of Corsao et al., Somatic Cell Molec. Genet 7: 603-616 (1981), total genomic DNA and the plasmid were cotransfected. The genomic DNA (60 μg) and plasmid DNA (6 μg) were mixed in 940 μl of 1 mM Tris·HCl (pH 7.5), 0.1 mM EDTA, after which 310 μl of 1M $CaCl_2$ was added. This solution was slowly added, under constant agitation, to 1.25 ml of 2xHBS (50 mM HEPES, 280 mM NaCl 1.5 mM Na_2HPO_4,
adjusted to pH 7.1 with NaOH). The calcium phosphate DNA precipitates were allowed to form for 30-45 minutes at room temperature, after which they were applied to 80 cm^2 tissue culture flasks which had been seeded 24 hours previously with $3x10^6$ MEL2.2 cells, in 22.5 ml of melanoma culture medium (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal calf serum. After 24 hours, the medium was replaced. Forty eight hours after transfection, the cells were harvested and seeded at $4x10^6$ cells per 80 cm^2 flask in melanoma culture medium supplemented with 2 mg/ml of geneticin. The geneticin serves as a selection marker.

Example 16

Thirteen days after transfection, geneticin-resistant colonies were counted, harvested, and cultured in nonselective

medium for 2 or 3 days. Transfected cells were then plated in 96-well microplates at 200 cells/well in 200 ul of culture medium with 20% fetal calf serum (FCS) in order to obtain approximately 30 growing colonies per well. The number of microcultures was aimed at achieving redundancy, i.e., such that every independent transfectant should be represented at least four times.

After 10 days, wells contained approximately $6x10^4$ cells. These cells were detached, and 1/3 of each microculture was transferred to a duplicate plate. After 6 hours, i.e., after readherence, medium was removed and 1500 anti-E CTL (CTL 82/30), were added to each well in 100 μl of CTL culture medium with 35 U/ml of IL-2. One day later, the supernatant (50 μl) was harvested and examined for TNF concentration, for reasons set forth in the following example.

Example 17

The size of the mammalian genome is $6x10^6$ kb. As the average amount of DNA integrated in each drug-resistant transfectant was expected to be about 200 kb, a minimum of 30,000 transfectants would need to be examined to ascertain whether antigen E had been transfected. Prior work with murine cells had shown that when a CTL stimulation assay was used, groups containing only 3% of cells expressing the antigen of interested could be identified. This should reduce the number of assays by a factor of 30. While an anti-E CTL assay, as described supra, in mixed E^+/E^- cells was helpful, it was not sufficient in that consistent results could not be obtained.

As a result, an alternative test was devised. Stimulation of CTLs was studied by release of tumor necrosis factor ("TNF") using well known methodologies which need not be repeated here. As described in Example 15, 1500 CTL 82/30 cells had been added per well of transfectants. These CTLs were collected 6 days after stimulation. As indicated supra, after 1/3 of the cells in each well had been removed and the remaining 2/3 ($4x10^4$) had readhered, the CTLs and IL-2 were added thereto. The 50 μl of supernatant was removed 24 hours

later and transferred to a microplate containing $3x10^4$ W13 (WEHI-164 clone 13; Espevik et al., J. Immunol. Meth. 95: 99-105 (1986)) cells in 50 μl of W13 culture medium (RPMI-1640, supplemented with L-arginine (116 mg/l), L-asparagine (36 mg/l), L-glutamine (216 mg/l), and 10% FCS supplemented with 2 μg of actinomycin D at 37% in an 8% CO_2 atmosphere. The cell line W13 is a mouse fibrosarcoma cell line sensitive to TNF. Dilutions of recombinant TNF-ß in RPMI 1640 were added to target cell controls.

The W13 cultures were evaluated after 20 hours of incubation, and dead cell percentage was measured using an adaptation of the colorimetric assay of Hansen et al., J. Immunol. Meth. 119: 203-210 (1989). This involved adding 50 ml of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide at 2.5 mg/ml in PBS, followed by two hours of incubation at 37°C. Dark blue formazan crystals were dissolved by adding 100 μl of lysis solution (1 volume N,N dimethyl formamide mixed at 37°C with two volumes of water containing 30% (w/v) sodium dodecyl sulphate, at pH 4.7 from 1.6% acetic acid and 2.5% 1N HCl). Plates were incubated at 37°C overnight, and ODs were taken at 570 nm using 650 nm as control. Dead cell percentage was determined via the formula:

$$100 \times \left[1 - \frac{100 - (OD_{570} \text{ sample well})}{OD_{570} \text{ well + medium}} \right]$$

following Espevik et al., J. Immunol. Meth. 95: 99-105 (1986). The results showed that even when the ratio of E^+/E^- cells was as low as 1/45, significant production of TNF was observed, thus showing active CTLs. This led to the decision to test the drug resistant transfectants in groups of 30.

Example 18

Cells were tested for TNF production as discussed in Example 17, supra. A total of 100 groups of E^- cells ($4x10^6$ cells/group) were tested following transfection, and $7x10^4$ independent geneticin resistant transfectants were obtained, for an average of 700 per group. Only one group of

transfected cells led to a microculture which caused anti-E antigen CTL clone 82/30 to produce TNF. Of 300 clones tested, 8 were positive. These clones were then tested for lysis by anti-E CTL, using the standard ^{51}Cr release assay, and were found to be lysed as efficiently as the original E^+ cell line. The transfectant E.T1, discussed herein, had the same lysis pattern as did MEL2.2 for CTLs against antigens B,C,D and F.

The fact that only one transfectant presented the antigen out of 70,000 geneticin resistance transfectants may at first seem very low, but it is not. The work described supra for P815 showed an average frequency of 1/13,000. Human DNA recipient MEL2.2 appears to integrate 5 times less DNA than P1.HTR.

Example 19

Once transfectant E.T1 was found, analysis had to address several questions including whether an E^+ contaminant of the cell population was the cause. The analysis of antigen presentation, described supra, shows that E.T1 is B^- and C^-, just like the recipient cell MEL2.2. It was also found to be $HPRT^-$, using standard selection procedures. All E^+ cells used in the work described herein, however, were $HPRT^+$.

It was also possible that an E^+ revertant of MEL2.2 was the source for E.T1. To test this, the observation by Perucho et al., Cell 22: 309-317 (1980), that cotransfected sequences usually integrate together at a single location of recipient genome was employed. If antigen E in a transfectant results from cotransfec-tion with pSVtkneoß, then sequences should be linked and deletion of the antigen might also delete the neighboring pSVtkneoß sequences. Wölfel et al., supra, has shown this to be true. If a normally E^- cell is transfected with pSVtkneoß, then sequences should be linked and deletion of the antigen might also delete the neighboring pSVtkneoß sequences. If a normally E^+ cell transfected with pSVtkneoß is E.T1, however, "co-deletion" should not take place. To test this, the transfectant E.T1 was subjected to immunoselection with 82/30, as described supra. Two antigen loss variants were obtained, which resisted lysis by this CTL.

Neither of these had lost geneticin resistance; however, Southern blot analysis showed loss of several neo^r sequences in the variants, showing close linkage between the E gene and neo^r gene in E.T1, leading to the conclusion that E.T1 was a transfectant.

Example 20

The E^+ subclone MZ2-MEL 4B was used as a source of DNA for preparation of a cosmid library. This library of nearly 700,000 cosmids was transfected into MZ2-MEL 2.2 cells, following the cosmid transfection protocols described supra.

By packaging the DNA of cosmid transfectants directly into lambda phase components, it is sometimes possible to retrieve cosmids that contain the sequences of interest. This procedure was unsuccessful here, so we rescued the transfected sequence by ligating DNA of the transfectant to appropriate restriction fragments of cosmid vector pTL6. This was tried with two transfectants and was successful with one of them. One cosmid, referred to as B3, was recovered from this experiment, and subjected to restriction endonuclease digestion via XmaI, or by BamHI digestion of a large, 12 kb XmaI transfected fragment. The fragments were cloned into vector pTZ 18R, and then transfected into MEL2.2. Again, TNF production was the measure by which successful transfection was determined. The experiments led to the determination of a gene sequence capable of transfecting antigen E on the 12 kb XmaI fragment, and then on the 2.4 kb fragment of BamHI digestion of the 12 kb segment.

The 2.4 kb fragment hybridizes with a 2.4 kb fragment from MZ2-MEL and with a T cell clone of patient MZ-2, as determined by Southern Blots (BamHI/SmaI digested DNA). The band is absent from E^- antigen loss variants of MZ2-MEL, as seen in Figure 12.

The sequence for the E antigen precursor gene has been determined, and is presented herein:

```
      |   10      |   20      |   30      |   40      |   50      |   60
    1 GGATCCAGGC CCTGCCAGGA AAAATATAAG GGCCCTGCGT GAGAACAGAG GGGGTCATCC 60
   61 ACTGCATGAG AGTGGGGATG TCACAGAGTC CAGCCCACCC TCCTGGTAGC ACTGAGAAGC 120
  121 CAGGGCTGTG CTTGCGGTCT GCACCCTGAG GGCCCGTGGA TTCCTCTTCC TGGAGCTCCA 180
  181 GGAACCAGGC AGTGAGGCCT TGGTCTGAGA CAGTATCCTC AGGTCACAGA GCAGAGGATG 240
  241 CACAGGGTGT GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300
  301 CAGGACACAT AGGACTCCAC AGAGTCTGGC CTCACCTCCC TACTGTCAGT CCTGTAGAAT 360
  361 CGACCTCTGC TGGCCGGCTG TACCCTGAGT ACCCTCTCAC TTCCTCCTTC AGGTTTTCAG 420
  421 GGGACAGGCC AACCCAGAGG ACAGGATTCC CTGGAGGCCA CAGAGGAGCA CCAAGGAGAA 480
  481 GATCTGTAAG TAGGCCTTTG TTAGAGTCTC CAAGGTTCAG TTCTCAGCTG AGGCCTCTCA 540
  541 CACACTCCCT CTCTCCCCAG GCCTGTGGGT CTTCATTGCC CAGCTCCTGC CCACACTCCT 600
  601 GCCTGCTGCC CTGACGAGAG TCATCATGTC TCTTGAGCAG AGGAGTCTGC ACTGCAAGCC 660
  661 TGAGGAAGCC CTTGAGGCCC AACAAGAGGC CCTGGGCCTG GTGTGTGTGC AGGCTGCCAC 720
  721 CTCCTCCTCC TCTCCTCTGG TCCTGGGCAC CCTGGAGGAG GTGCCCACTG CTGGGTCAAC 780
  781 AGATCCTCCC CAGAGTCCTC AGGGAGCCTC CGCCTTTCCC ACTACCATCA ACTTCACTCG 840
  841 ACAGAGGCAA CCCAGTGAGG GTTCCAGCAG CCGTGAAGAG GAGGGGCCAA GCACCTCTTG 900
  901 TATCCTGGAG TCCTTGTTCC GAGCAGTAAT CACTAAGAAG GTGGCTGATT TGGTTGGTTT 960
  961 TCTGCTCCTC AAATATCGAG CCAGGGAGCC AGTCACAAAG GCAGAAATGC TGGAGAGTGT 1020
 1021 CATCAAAAAT TACAAGCACT GTTTTCCTGA GATCTTCGGC AAAGCCTCTG AGTCCTTGCA 1080
 1081 GCTGGTCTTT GGCATTGACG TGAAGGAAGC AGACCCCACC GGCCACTCCT ATGTCCTTGT 1140
 1141 CACCTGCCTA GGTCTCTCCT ATGATGGCCT GCTGGGTGAT AATCAGATCA TGCCCAAGAC 1200
 1201 AGGCTTCCTG ATAATTGTCC TGGTCATGAT TGCAATGGAG GGCGGCCATG CTCCTGAGGA 1260
 1261 GGAAATCTGG GAGGAGCTGA GTGTGATGGA GGTGTATGAT GGGAGGGAGC ACAGTGCCTA 1320
 1321 TGGGGAGCCC AGGAAGCTGC TCACCCAAGA TTTGGTGCAG GAAAAGTACC TGGAGTACCG 1380
 1381 GCAGGTGCCG GACAGTGATC CCGCACGCTA TGAGTTCCTG TGGGGTCCAA GGGCCCTCGC 1440
 1441 TGAAACCAGC TATGTGAAAG TCCTTGAGTA TGTGATCAAG GTCAGTGCAA GAGTTCGCTT 1500
 1501 TTTCTTCCCA TCCCTGCGTG AAGCAGCTTT GAGAGAGGAG GAAGAGGGAG TCTGAGCATG 1560
 1561 AGTTGCAGCC AAGGCCAGTG GGAGGGGGAC TGGGCCAGTG CACCTTCCAG GGCCGCGTCC 1620
 1621 AGCAGCTTCC CCTGCCTCGT GTGACATGAG GCCCATTCTT CACTCTGAAG AGAGCGGTCA 1680
 1681 GTGTTCTCAG TAGTAGGTTT CTGTTCTATT GGGTGACTTG GAGATTTATC TTTGTTCTCT 1740
 1741 TTTGGAATTG TTCAAATGTT TTTTTTTAAG GGATGGTTGA ATGAACTTCA GCATCCAAGT 1800
 1801 TTATGAATGA CAGCAGTCAC ACAGTTCTGT GTATATAGTT TAAGGGTAAG AGTCTTGTGT 1860
 1861 TTTATTCAGA TTGGGAAATC CATTCTATTT TGTGAATTGG GATAATAACA GCAGTGGAAT 1920
 1921 AAGTACTTAG AAATGTGAAA AATGAGCAGT AAAATAGATG AGATAAAGAA CTAAAGAAAT 1980
 1981 TAAGAGATAG TCAATTCTTG CCTTATACCT CAGTCTATTC TGTAAAATTT TTAAAGATAT 2040
 2041 ATGCATACCT GGATTTCCTT GGCTTCTTTG AGAATGTAAG AGAAATTAAA TCTGAATAAA 2100
 2101 GAATTCTTCC TGTTCACTGG CTCTTTTCTT CTCCATGCAC TGAGCATCTG CTTTTTGGAA 2160
 2161 GGCCCTGGGT TAGTAGTGGA GATGCTAAGG TAAGCCAGAC TCATACCCAC CCATAGGGTC 2220
 2221 GTAGAGTCTA GGAGCTGCAG TCACGTAATC GAGGTGGCAA GATGTCCTCT AAAGATGTAG 2280
 2281 GGAAAAGTGA GAGAGGGGTG AGGGTGTGGG GCTCCGGGTG AGAGTGGTGG AGTGTCAATG 2340
 2341 CCCTGAGCTG GGGCATTTTG GGCTTTGGGA AACTGCAGTT CCTTCTGGGG GAGCTGATTG 2400
 2401 TAATGATCTT GGGTGGATCC                                           2420
      |   10      |   20      |   30      |   40      |   50      |   60
```

Example 21

After the 2.4 kb genomic segment had been identified, studies were carried out to determine if an "E^+" subline expressed any homologous DNA. Cell line MZ2-MEL 3.0 was used as a source, and a cDNA library was prepared from its mRNA, using art known techniques. The 2.4 kb segment was used as a probe, and mRNA of about 1.8 kb was identified as homologous, using Northern blot analysis. When cDNA was screened, clones were obtained showing almost complete identity to parts of the 2.4 kb fragment. Two exons were thus identified. An additional exon was located upstream of these, via sequencing segments of cosmid B3 located in front of the 2.4 kb BamHI fragment. The gene extends over about 4.5 kb, as shown in Figure 8. The starting point of the transcribed region was confirmed using PCR for the 5' end of the cDNA. The three exons comprise 65, 73, and 1551 base pairs. An ATG is located at position 66 of exon 3, followed by an 828 base pair reading frame.

Example 22

To determine if smaller segments of the 2.4 kb fragment could transfer the expression of antigen E, smaller pieces corresponding to the larger gene were prepared, using art recognized techniques, and transferred into E^- cells. Figure 8 shows the boundaries of the three segments.

Transfer of antigen expression in this manner indicates that the gene codes for the antigen precursor, rather than coding for a protein which activates the antigen.

Example 23

The probing of cDNA described supra revealed, surprisingly, two different but closely related cDNAs. These cDNAs, when tested, did not transfer expression of antigen E, but they do show substantial homology to the first cDNA segment. The three segments, appear to indicate a newly recognized family of genes, referred to as "MAGE" for "melanoma antigen". In Figure 9, "mage-1" directs expression of the antigen from MZ2 cells. Portions of the third exon of each gene are presented in Figure 9. The second and third

sequences are more closely related to each other than the first (18.1 and 18.9% difference compared to the first; 12% with each other). Out of 9 cDNA clones obtained, three of each type were obtained, suggesting equal expression. "MAGE" as used hereafter refers to a family of molecules, and the nucleic acids coding for them. These nucleic acids share a certain degree of homology and are expressed in tumor cells including several types of human tumor cells as well as in human tumors. The family is referred to as "MAGE" because the first members were identified in human melanoma cells. As the experiments which follow indicate, however, the members of the MAGE family are not at all restricted to melanoma tumors; rather, MAGE refers to a family of tumor rejection antigen precursors and the nucleic acid sequences coding therefore. The antigens resulting therefrom are referred to herein as "MAGE TRAs" or "melanoma antigen tumor rejection antigens"

Example 24

Experiments with mouse tumors have demonstrated that new antigens recognized by T cells can result from point mutations that modify active genes in a region that codes for the new antigenic peptide. New antigens can also arise from the activation of genes that are not expressed in most normal cells. To clarify this issue for antigen MZ2-E, the mage-1 gene present in the melanoma cells was compared to that present in normal cells of patient MZ2.

Amplification by polymerase chain reaction (PCR) of DNA of phytohemagglutinin-activated blood lymphocytes using primers surrounding a 1300 bp stretch covering the first half of the 2.4 kb fragment was carried out. As expected, a PCR product was obtained whereas none was obtained with the DNA of the E^- variant. The sequence of this PCR product proved identical to the corresponding sequence of the gene carried by the E^+ melanoma cells. Moreover, it was found that antigen MZ2-E was expressed by cells transfected with the cloned PCR product. This result suggests that the activation of a gene normally silent is responsible for the appearance of tumor rejection antigen MZ2-E.

Example 25

In order to evaluate the expression of gene mage-1 by various normal and tumor cells, Northern blots were hybridized with a probe covering most of the third exon. In contrast with the result observed with human tumor cell line MZ2-MEL 3.0, no band was observed with RNA isolated from a CTL clone of patient MZ2 and phytohemagglutinin-activated blood lymphocytes of the same patient. Also negative were several normal tissues of other individuals (Figure 10 and Figure 11). Fourteen melanoma cell lines of other patients were tested. Eleven were positive with bands of varying intensities. In addition to these culture cell lines, four samples of melanoma tumor tissue were analyzed. Two samples, including a metastasis of patient MZ2 proved positive, excluding the possibility that expression of the gene represented a tissue culture artefact. A few tumors of other histological types, including lung tumors were tested. Most of these tumors were positive (Figures 10 and 11). These results indicated that the MAGE gene family is expressed by many melanomas and also by other tumors. However, they provided no clear indication as to which of genes mage-1, 2 or 3 were expressed by these cells, because the DNA probes corresponding to the three genes cross-hybridized to a considerable extent. To render this analysis more specific, PCR amplification and hybridization with highly specific oligo- nucleotide probes were used. cDNAs were obtained and amplified by PCR using oligonucleotide primers corresponding to sequences of exon 3 that were identical for the three MAGE genes discussed herein. The PCR products were then tested for their ability to hybridize to three other oligonucleotides that showed complete specificity for one of the three genes (Figure 9). Control experiments carried out by diluting RNA of melanoma MZ2-MEL 3.0 in RNA from negative cells indicated that under the conditions used herein the intensity of the signal decreased proportionally to the dilution and that positive signals could still be detected at a dilution of 1/300. The normal cells (lymphocytes) that were tested by PCR were confirmed to be negative for the

expression of the three MAGE genes, suggesting therefore a level of expression of less than 1/300th that of the MZ2 melanoma cell line (Figure 11). For the panel of melanoma cell lines, the results clearly showed that some melanomas expressed MAGE genes mage 1, 2 and 3 whereas other expressed only mage-2 and 3 (Figures 11 and 10). Some of the other tumors also expressed all three genes whereas others expressed only mage-2 and 3 or only mage-3. It is impossible to exclude formally that some positive PCR results do not reflect the expression of one of the three characterized MAGE genes but that of yet another closely related gene that would share the sequence of the priming and hybridizing oligonucleotides. It can be concluded that the MAGE gene family is expressed by a large array of different tumors and that these genes are silent in the normal cells tested to this point.

Example 26

The availability of a sequence that transfects at high efficiency and efficiently expresses a TRAP made it possible to search for the associated major histocompatibility complex (MHC) class I molecule. The class I specificities of patient MZ2 are HLA-A1, A29, B37, B44 and C6. Four other melanomas of patients that had A1 in common with MZ2 were cotransfected with the 2.4 kb fragment and pSVtkneoß. Three of them yielded neo^r transfectants that stimulated TNF release by anti-E CTL clone 82/30, which is CD8+ (Figure 10). No E- transfectant was obtained with four other melanomas, some of which shared A29, B44 or C6 with MZ2. This suggests that the presenting molecule for antigen MZ2-E is HLA-A1. In confirmation, it was found that, out of 6 melanoma cell lines derived from tumors of HLA-A1 patients, two stimulated TNF release by anti-E CTL clone 82/30 of patient MZ2. One of these tumor cell lines, MI13443-MEL also showed high sensitivity to lysis by these anti-E CTL. These two melanomas were those that expressed mage-1 gene (Figure 13). Eight melanomas of patients with HLA haplotypes that did not include A1 were examined for their sensitivity to lysis and for their ability to stimulate TNF release by the CTL. None was found to be positive. The

ability of some human anti-tumor CTL to lyse allogeneic tumors sharing an appropriate HLA specificity with the original tumor has been reported previously (Darrow, et al., J. Immunol. 142: 3329 (1989)). It is quite possible that antigenic peptides encoded by genes mage 2 and 3 can also be presented to autologous CTL by HLA-A1 or other class I molecules, especially in view of the similar results found with murine tumors, as elaborated upon supra.

Example 27

As indicated supra, melanoma MZ2 expressed antigens F, D and A', in addition to antigen E. Following the isolation of the nucleic acid sequence coding for antigen E, similar experiments were carried out to isolate the nucleic acid sequence coding for antigen F.

To do this, cultures of cell line MZ2-MEL2.2, an E^- cell line described supra, were treated with anti-F CTL clone 76/6, in the same manner described for treatment with anti-E CTL clones. This resulted in the isolation of an F antigen loss variant, which was then subjected to several rounds of selection. The resulting cell line, "MZ2-MEL2.2.5" was completely resistant to lysis by anti-F CTLs, yet proved to be lysed by anti-D CTLs.

Again, following the protocols set forth for isolation of antigen -E precursor DNA, the F^- variant was transfected with genomic DNA from F^+ cell line MZ2-MEL3.0. The experiments yielded 90,000 drug resistant transfectants. These were tested for MZ2-F expression by using pools of 30 cells in the TNF detection assay elaborated upon supra. One pool stimulated TNF release by anti-F CTLs, and was cloned. Five of 145 clones were found to stimulate anti-F CTLs. Lysis assays, also following protocols described supra, confirmed (i) expression of the gene coding for antigen F, and (ii) presentation of antigen F itself.

Example 28

Following identification of F^+ cell lines, the DNA therefrom was used to transfect cells. To do this, a cosmid library of F^+ cell line MZ2-MEL.43 was prepared, again using

the protocols described supra. The library was divided into 14 groups of about 50,000 cosmids, and DNA from each group was transfected into MZ2-MEL2.2.5. Transfectants were then tested for their ability to stimulate TNF release from anti-F CTL clone 76/6. Of 14 groups of cosmids, one produced two independent transfectants expressing antigen F; a yield of two positives out of 17,500 geniticin resistant transfectants.

Example 29

The existence of a gene family was suggested by the pattern observed on the Southern blot (Figure 12). To do this, the 2.4 kb BamHI fragment, which transferred the expression of antigen M22-E, was labelled with 32p and used as a probe on a Southern Blot of BamHI digested DNA of E + cloned subclone M22-MEL2.2. Hybridization conditions included 50 $\mu l/cm^2$ of 3.5xSSC, 1xDenhardt's solution; 25 mM sodium phosphate buffer (pH 7.0), 0.5% SDS, 2mM EDTA, where the 2.4 kb probes had been labelled with [α^{32}p]dCTP (2-3000 Ci/mole), at $3x10^6$ cpm/ml. Hybridization was carried out for 18 hours at 65°C. After this, the membranes were washed at 65°C four times for one hour each in 2xSSC, 0.1% SDS, and finally for 30 minutes in 0.1xSSC, 0.1% SDS. To identify hybridization, membranes were autoradiographed using Kodak X-AR film and Kodak X-Omatic fine intensifying screens.

In the following examples, whenever "hybridization" is referred to, the stringency conditions used were similar to those described supra. "Stringent conditions" as used herein thus refers to the foregoing conditions; subject to routine, art recognized modification.

Example 30

The cDNA coding for mage 4 was identified from a sample of the human sarcoma cell line LB23-SAR. This cell line was found to not express mage 1, 2 or 3, but the mRNA of the cell line did hybridize to the 2.4 kb sequence for mage 1. To study this further, a cDNA library was prepared from total LB23-SAR mRNA, and was then hybridized to the 2.4 kb fragment. A cDNA sequence was identified as hybridizing to this probe, and is identified hereafter as mage 4.

Example 31

Experiments were carried out using PHA-activated lymphocytes from patient "MZ2", the source of the "MZ" cells discussed supra. An oligonucleotide probe which showed homology to mage 1 but not mage 2 or 3 was hybridized with a cosmid library derived from the PHA activated cells. The size of the hybridizing BamHI cosmid fragment, however, was 4.5 kb, thus indicating that the material was not mage 1; however, on the basis of homology to mage 1-4, the fragment can be referred to as "mage 5". The sequence of MAGE 5 is presented in SEQ ID NO: 16.

Example 32

Melanoma cell line LB-33-MEL was tested. Total mRNA from the cell line was used to prepare cDNA, which was then amplified with oligos CHO9: (ACTCAGCTCCTCCCAGATTT), and CHO10: (GAAGAGGAGGGGCCAAG). These oligos correspond to regions of exon 3 that are common to previously described mage 1, 2 and 3.

To do this, 1 μg of RNA was diluted to a total volume of 20 μl, using 2 μl of 10x PCR buffer, 2 μl of each of 10 mM dNTP, 1.2 μl of 25 mM $MgCl_2$, 1 μl of an 80 mM solution of CHO9, described supra, 20 units of RNAsin, and 200 units of M-MLV reverse transcriptase. This was followed by incubation for 40 minutes at 42°C. PCR amplification followed, using 8 μl of 10x PCR buffer, 4.8 μl of 25 mM $MgCl_2$, 1 μl of CHO10, 2.5 units of Thermus acquaticus ("Taq") polymerase, and water to a total volume of 100 μl. Amplification was then carried out for 30 cycles (1 minute 94°C; 2 minutes at 52°C, 3 minutes at 72°C). Ten μl of each reaction were then size fractionated on agarose gel, followed by nitrocellulose blotting. The product was found to hybridize with oligonucleotide probe CHO18 (TCTTGTATCCTGGAGTCC). This probe identified mage 1 but not mage 2 or 3. However, the product did not hybridize to probe SEQ 4 (TTGCCAAGATCTCAGGAA). This probe also binds mage 1 but not 2 and 3. This indicated that the PCR product contained a sequence that differed from mage 1, 2 and 3. Sequencing of this fragment also indicated differences with

respect to mage 4 and 5. These results indicate a sequence differing from previously identified mage 1, 2, 3, 4 and 5, and is named mage 6.

Example 33

In additional experiments using cosmid libraries from PHA-activated lymphocytes of MZ2, the 2.4 kb mage 1 fragment was used as a probe and isolated a complementary fragment. This clone, however, did not bind to oligonucleotides specific for mage 1, 2, 3 or 4. The sequence obtained shows some homology to exon 3 of mage 1, and differs from mages 1-6. It is referred to as mage 7 hereafter. Additional screenings yielded mage 8-11.

Example 34

The usefulness of the TRAPs, as well as TRAs derived therefrom, was exemplified by the following.

Exon 3 of mage 1 was shown to transfer expression of antigen E. As a result, it was decided to test whether synthetic peptides derived from this exon 3 could be used to confer sensitivity to anti-E CTL.

To do this, and using standard protocols, cells normally insensitive to anti-E/CTLs were incubated with the synthetic peptides derived from Exon 3.1. Using the CTL lytic assays described supra on P815A, and a peptide concentration of 3 mM, the peptide Glu-Ala-Asp-Pro-Thr-Gly-His-Ser-Tyr was shown to be best. The assay showed lysis of 30%, indicating conferring of sensitivity to the anti-E CTL.

Example 35

Nucleic acid sequences referred to as "smage" were isolated from murine cells. Using the protocols described supra, a cosmid library was prepared from the DNA of normal DBA/2 kidney cells, using cosmid vector C2RB. As a probe, the 2.4 kb BamHI fragment of MAGE-1 was used. The DNA was blotted to nylon filters, and these were washed in 2xSSC at 65°C to identify the smage material.

Example 36

Further tissue samples were tested for the presence of MAGE genes, using the protocols discussed supra. Some of

these results follow.

There was no expression of the MAGE genes in brain or kidney tumor tissue. Colon tumor tissue showed expression of MAGE 1, 2, 3 and 4, although not all tumors tested showed expression of all MAGE genes. This is also true for pancreatic tumor (MAGE 1); non-small cell lung (MAGE 1, 2, 3 and 4), prostate (MAGE 1), sarcomas (MAGE 1, 2, 3 and 4), breast (MAGE 1, 2 and 3), and larynx (MAGE 1 and 4).

Example 37

A cytolytic CTL clone "20/38" was obtained from peripheral blood lymphocytes of melanoma patient MZ2. This clone is described by Van den Eynde et al., Int. J. Cancer 44: 634-640 (1989), the disclosure of which is incorporated by reference. The CTL clone has isolated following Herin et al., Int. J. Cancer 39: 390-396 (1987), which is incorporated by reference. The assay is described herein, however. Autologous melanoma cells were grown in vitro, and then resuspended at 10^7 cells/ml in DMEM, supplemented with 10% HEPES and 30% FCS, and incubated for 45 minutes at 37°C with 200 μCi/ml of $Na(^{51}Cr)O_4$. Labelled cells were washed three times with DMEM, supplemented with 10 mM HEPES. These were then resuspended in DMEM supplemented with 10 mM HEPES and 10% FCS, after which 100 μl aliquots containing 10^3 cells, were distributed into 96 well microplates. Samples of the CTL clone were added in 100 ul of the same medium, and assays were carried out in duplicate. Plates were centrifuged for four minutes at 100g, and incubated for four hours at 37°C in a 5.5% CO_2 atmosphere.

Plates were centrifuged again, and 100 ul aliquots of supernatant were collected and counted. Percentage of ^{51}Cr release was calculated as follows:

$$\% \ ^{51}Cr \text{ release} = \frac{(ER-SR)}{(MR-SR)} \times 100$$

where ER is observed, experimental ^{51}Cr release, SR is spontaneous release measured by incubating 10^3 labeled cells in 200 ul of medium alone, and MR is maximum release, obtained

by adding 100 ul 0.3% Triton X-100 to target cells.

Those mononuclear blood samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology.

The same method was used to test target K562 cells. When EBV-B cells were used, the only change was the replacement of DMEM medium by Hank's medium, supplemented with 5% FCS.

These experiments led to isolation of CTL clone 20/38.

Figure 1 presents the results of these assays. Specifically, it will be seen that the CTL clone lysed autologous melanoma cell line MZ2-MEL.3.0, but did not lyse EBV-B cell lines, fibroblasts, K562 or non-autologous melanoma cell line SK-MEL-29.

Example 38

Once the CTL clone was recognized as being specific for the autologous cell line, it was tested for antigenic specificity. To do this, antigen loss variants derived from patient MZ2 were tested in the same type of chromium release assay described above. These target lines were MZ2-MEL 3.0, which is D^+, E^+, F^+, A^+, MZ2-MEL.61, which is D^-, MZ2-MEL 2.2, which is E^-, and MZ2-MEL.4, which is F^-. In addition to CTL clone 20/38, clones which are known to be anti-A (CTL 28/336), anti-F (CTL 76/6), and anti-E (CTL 22/13) were tested.

These results are set forth in figure 15. It will be seen that CTL clone 20/38 lysed all the cell lines leading to chromium release except D^- cell line MZ2-MEL.61, thus indicating that the CTL clone is anti-D. This result was confirmed, in experiments not included herein, by experiments where TNF release by the CTL clone was observed only in the presence of melanoma lines presenting antigen D.

Example 39

Once antigen D was identified as the target molecule, studies were carried out to determine the HLA type which presented it. The experiments described in example A showed that antigen D was presented by MZ2-MEL, and this cell line's HLA specificity is known (i.e., A1, A29, B37, B44, Cw6,

C.cl.10). It was also known, however, that a variant of MZ2-MEL which had lost HLA molecules A29, B44 and C.cl.10 still expressed antigen D, so these could be eliminated from consideration. Studies were not carried out on lines expressing B37, as none could be found.

In all, 13 allogeneic lines were tested, which expressed either HLA-A1 (10 of 13), or Cw6 (3 of 13). The cell lines were tested for their ability to stimulate release of TNF by CTL clone 20/38, using the method of Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference. This assay measures TNF release via testing toxicity of supernatants on WEHI 164-13 cells.

In the assays, cell samples (3000, 10,000 or 30,000 cells) from the allogeneic lines were cultured in the presence of 1500 cells of the CTL clone, and 25 u/ml of IL-2. Twenty-four hours later, the supernatant from the culture was tested against the WEHI cells for toxicity. The results are presented in Table 3, which follows.

Eight cell lines were found to stimulate TNF release from the CTL clone 20/38. All of these lines were HLA-A1. None of the Cw6 presenting lines did so.

The cell lines were also assayed to determine MAGE expression. All eight of the lines which stimulated TNF release expressed MAGE-3, whereas the two HLA-A1 lines which were negative did not.

Example 40

In view of the results set forth in example C, experiments were carried out to determine if antigen D was in fact a tumor rejection antigen derived from MAGE-3. To do this, recipient COS7 cells were transfected with 100ng of the gene for HLA-A1 cloned into pcDNA I/Amp, and 100 ng of one of (a) cDNA for MAGE-1 cloned into pcDNA I/Amp, (b) cDNA for MAGE-2 cloned into pcDSRα, or (c) cDNA for MAGE-3 cloned into pcDSRα. The transfecting sequences were ligated into the plasmids in accordance with manufacturer's instructions. Samples of COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbeco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30 μl/well of DMEM medium containing 10% Nu serum, 400 μg/ml DEAE-dextran, 100 μM chloroquine, and the plasmids described above. Following four hours of incubation at 37°C, the medium was removed, and replaced by 50 μl of PBS containing 10% DMSO. This medium was removed after two minutes and replaced by 200 μl of DMEM supplemented with 10% of FCS.

Following this change in medium, COS cells were incubated for 24 hours at 37°C. Medium was then discarded, and 1500 cells of CTL clones 20/38 were added, in 100 μl of Iscove medium containing 10% pooled human serum, supplemented with 25 u/ml of IL-2. Supernatant was removed after 24 hours, and TNF content was determined in an assay on WEHI cells, as described by Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference. These results are shown in Figure 16.

It will be seen that the CTL clone was strongly stimulated by COS7 cells transfected with HLA-A1 and MAGE-3, but not by the cells transfected with the other mage genes. This leads to the conclusion that antigen D is a tumor rejection antigen derived from the tumor rejection antigen precursor coded by gene MAGE-3, and that this TRA is presented

by HLA-A1 molecules.

The foregoing disclosure, including the examples, places many tools of extreme value in the hands of the skilled artisan. To begin, the examples identify and provide a methodology for isolating nucleic acid molecules which code for tumor rejection antigen precursors as well as the nucleic acid molecules complementary thereto. It is known that DNA exists in double stranded form, and that each of the two strands is complementary to the other. Nucleic acid hybridization technology has developed to the point where, given a strand of DNA, the skilled artisan can isolate its complement, or synthesize it.

"Nucleic acid molecule" as used herein refers to all species of DNA and RNA which possess the properties discussed supra. Genomic and complementary DNA, or "cDNA" both code for particular proteins, and as the examples directed to isolation of MAGE coding sequences show, this disclosure teaches the artisan how to secure both of these.

Similarly, RNA molecules, such as mRNA can be secured. Again, with reference to the skilled artisan, once one has a coding sequence in hand, mRNA can be isolated or synthesized.

Complementary sequences which do not code for TRAP, such as "antisense DNA" or mRNA are useful, e.g., in probing for the coding sequence as well as in methodologies for blocking its expression.

It will also be clear that the examples show the manufacture of biologically pure cultures of cell lines which have been transfected with nucleic acid sequences which code for or express the TRAP molecules. Such cultures can be used as a source for tumor rejection antigens, e.g., or as therapeutics. This aspect of the invention is discussed infra.

Cells transfected with the TRAP coding sequences may also be transfected with other coding sequences. Examples of other coding sequences include cytokine genes, such as interleukins (e.g., IL-2 or IL-4), or major histocompatibility complex (MHC) or human leukocyte antigen (HLA) molecules.

Cytokine gene transfection is of value because expression of these is expected to enhance the therapeutic efficacy of the biologically pure culture of the cells in vivo. The art is well aware of therapies where interleukin transfectants have been administered to subjects for treating cancerous conditions. In a particularly preferred embodiment, cells are transfected with sequences coding for each of (i) a TRAP molecule, (ii) an HLA/MHC molecule, and (iii) a cytokine.

Transfection with an MHC/HLA coding sequence is desirable because certain of the TRAs may be preferentially or specifically presented only by particular MHC/HLA molecules. Thus, where a recipient cell already expresses the MHC/HLA molecule associated with presentation of a TRA, additional transfection may not be necessary although further transformation could be used to cause over-expression of the antigen. On the other hand, it may be desirable to transfect with a second sequence when the recipient cell does not normally express the relevant MHC/HLA molecule. It is to be understood, of course, that transfection with one additional sequence does not preclude further transfection with other sequences.

The term "biologically pure" as used in connection with the cell line described herein simply means that these are essentially free of other cells. Strictly speaking, a "cell line" by definition is "biologically pure", but the recitation will establish this fully.

Transfection of cells requires that an appropriate vector be used. Thus, the invention encompasses expression vectors where a coding sequence for the TRAP of interest is operably linked to a promoter. The promoter may be a strong promoter, such as those well known to the art, or a differential promoter, i.e., one which is operative only in specific cell types. The expression vectors may also contain all or a part of a viral or bacterial genome, such as vaccinia virus or BCG. Such vectors are especially useful in preparing vaccines.

The expression vectors may incorporate several coding sequences, as long as the TRAP sequence is contained therein.

The cytokine and/or MHC/HLA genes discussed supra may be included in a single vector with the TRAP sequence. Where this is not desired, then an expression system may be provided, where two or more separate vectors are used where each coding sequence is operably linked to a promoter. Again, the promoter may be a strong or differential promoter. Co-transfection is a well known technique, and the artisan in this field is expected to have this technology available for utilization. The vectors may be constructed so that they code for the TRA molecule directly, rather than the TRAP molecule. This eliminates the need for post-translational processing.

As the foregoing discussion makes clear, the sequences code for "tumor rejection antigen precursors" ("TRAPs") which, in turn, are processed into tumor rejection antigens ("TRAs"). Isolated forms of both of these categories are described herein, including specific examples of each. Perhaps their most noteworthy aspect is as vaccines for treating various cancerous conditions. The evidence points to presentation of TRAs on tumor cells, followed by the development of an immune response and deletion of the cells. The examples show that when various TRAs are administered to cells, a CTL response is mounted and presenting cells are deleted. This is behavior characteristic of vaccines, and hence TRAPs, which are processed into TRAs, and the TRAs themselves may be used, either alone or in pharmaceutically appropriate compositions, as vaccines. Similarly, presenting cells may be used in the same manner, either alone or as combined with ingredients to yield pharmaceutical compositions. Additional materials which may be used as vaccines include isolated cells which present the TRA molecule on their surface, as well as TRAP fragments, mutated viruses, especially etiolated forms, and transfected bacteria. "Fragments" as used herein refers to peptides which are smaller than the TRA, but which possess the properties required of a vaccine, as discussed supra. Another vaccine comprises or consists of complexes of TRA and HLA molecule. Vaccines of the type described herein may be used preventively, i.e., via administration to a subject in an

amount sufficient to prevent onset of a cancerous condition.

The generation of an immune response, be it T-cell or B-cell related, is characteristic of the effect of the presented tumor rejection antigen. With respect to the B-cell response, this involves, inter alia, the generation of antibodies to the TRA, i.e., which specifically bind thereto. In addition, the TRAP molecules are of sufficient size to render them immunogenic, and antibodies which specifically bind thereto are a part of this invention. These antibodies may be polyclonal or monoclonal, the latter being prepared by any of the well recognized methodologies for their preparation which need not be repeated here. For example, mAbs may be prepared using an animal model, e.g., a Balb/C mouse or in a test tube, using, e.g., EBV transformants. In addition, antiserum may be isolated from a subject afflicted with a cancerous condition where certain cells present a TRA. Such antibodies may also be generated to epitopes defined by the interaction of TRA and HLA/MHC molecules.

Review of the foregoing disclosure will show that there are a number of facets to the system which may be referred to as "tumor rejection antigen presentation and recognition". Recognition of these phenomena has diagnostic consequences. For example, the existence of specific CTL clones, or antibodies to the TRA makes it possible to diagnose or monitor cancerous conditions (explained infra), by monitoring the CTLs in a sample from a subject, binding of antibodies to TRAs, or the activity of anti-TRA CTLs in connection with subject samples. Similarly, the expression of nucleic acid molecules for TRAPs can be monitored via amplification (e.g., "polymerase chain reaction"), anti-sense hybridization, probe technologies, and so forth. Various subject samples, including body fluids (blood, serum, and other exudates, e.g.), tissues and tumors may be so assayed.

A particular manner of diagnosis is to use an adaptation of the standard "tuberculin test" currently used for diagnosis of tuberculosis. This standard skin test administers a stable form of "purified protein derivative" or "PPD" as a diagnostic

aid. In a parallel fashion, TRAs in accordance with this invention may be used in such a skin test as a diagnostic aid or monitoring method.

The term "cancerous condition" is used herein to embrace all physiological events that commence with the initiation of the cancer and result in final clinical manifestation. Tumors do not spring up "ab initio" as visible tumors; rather there are various events associated with the transformation of a normal cell to malignancy, followed by development of a growth of biomass, such as a tumor, metastasis, etc. In addition, remission may be conceived of as part of "a cancerous condition" as tumors seldom spontaneously disappear. The diagnostic aspects of this invention include all events involved in carcinogenesis, from the first transformation to malignancy of a single cell, through tumor development and metastasis, as well as remission. All are embraced herein.

Where "subject" is used, the term embraces any species which can be afflicted with a cancerous condition. This includes humans and non-humans, such as domesticated animals, breeding stock, and so forth.

There are therapeutic aspects of this invention as well. The efficacy of administration of effective amounts of TRAPs and TRAs as vaccines has already been discussed supra. Similarly, one may develop the specific CTLs in vitro and then administer these to the subject. Antibodies may be administered, either polyclonal or monoclonal, which specifically bind to cells presenting the TRA of interest. These antibodies may be coupled to specific antitumor agents, including, but not being limited to, methotrexate radio-iodinated compounds, toxins such as ricin, other cytostatic or cytolytic drugs, and so forth. Thus, "targeted" antibody therapy is included herein, as is the application of deletion of the cancerous cells by the use of CTLs.

The data from examples 37-40 show that a tumor rejection antigen derived from MAGE-3 is presented by HLA-A1 molecules. As such, in addition to the nucleic acid molecules coding for this TRAP, the TRAP itself as coded for by the sequences,

vectors, cell lines, etcetera which incorporate this nucleic acid molecule, the invention also encompasses combination of the molecules coding for the MAGE-3 TRAP and HLA-A1. Thus, co-transfectants, vectors containing coding sequences for both, expression systems such as kits, or separate vectors, and so forth, are all embraced by the invention. Similarly, the vaccines discussed supra can be made by incorporating the TRAP from MAGE-3 and an adjuvant.

It is to be understood that a given TRAP may yield more than one TRA. In the case of MAGE-3, it has been shown that antigen D, as the term is used herein, derives therefrom, and one aspect of the invention is this isolated tumor rejection antigen. Another is isolated complexes of the TRA and its presenting molecule, i.e., HLA-A1.

The identification of MAGE-3 derived TRAs as being presented by HLA-A1 molecules suggests various therapeutic and diagnostic approaches. In a therapeutic context, e.g., the treatment of a disorder characterized by MAGE-3 expression may be treated in a number of ways, "disorder" being used to refer to any pathological condition where MAGE-3 TRAP is expressed, such as cancer (e.g., melanoma).

Therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of TRA presenting cells, such as HLA-A1 cells. One such approach is the administration of CTLs specific to the complex to a subject with abnormal cells of the phenotype at issue. it is within the skill of the artisan to develop such CTLs in vitro. Specifically, a sample of cells, such as blood cells, are contacted to a cell presenting the complex and capable of provoking a specific CTL to proliferate. The target cell can be a transfectant, such as a COS cell of the type described supra. These transfectants present the desired complex on their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells.

To detail the therapeutic methodology, referred to as

adoptive transfer (Greenberg, J. Immunol. 136(5): 1917 (1986); Reddel et al., Science 257: 238 (7-10-92); Lynch et al., Eur. J. Immunol. 21: 1403-1410 (1991); Kast et al., Cell 59: 603-614 (11-17-89)), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA containing the indicated sequences. Once isolated, such cells can be used with a sample of a subject's abnormal cells to determine lysis in vitro. If lysis is observed, then the use of specific CTLs in such a therapy may alleviate the condition associated with the abnormal cells. A less involved methodology examines the abnormal cells for HLA phenotyping, using standard assays, and determines expression via amplification using, e.g., PCR.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked in vivo, using a number of approaches. One approach, i.e., the use of non-proliferative cells expressing the complex, has been elaborated upon supra. The cells used in this approach may be those that normally express the complex, such as irradiated melanoma cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al., Proc. Natl. Acad. Sci. USA 88: 110-114 (January, 1991) exemplifies this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. In these

systems, the gene of interest is carried by, e.g., a Vaccinia virus or the bacteria BCG, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate. A similar effect can be achieved by combining the tumor rejection antigen or the precursor itself with an adjuvant to facilitate incorporation into HLA-A1 presenting cells which present the HLA molecule of interest. The TRAP is processed to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing. Thus, one may treat disorders where a MAGE-3 derived TRA is presented by HLA-A1 molecules, or by any HLA molecule.

In a diagnostic context, one may determine a disorder, as the term is used herein, by assaying for expression of the TRAP. This can be done directly (via, e.g., a PCR assay for TRAP sequences), or indirectly, via assaying for a MAGE-3 derived TRA, as the TRA's presence means that the TRAP is or was expressed.

It will be noted that two nucleic acid molecules are presented herein, i.e., MAGE-3 and MAGE-31, each of which code for TRAP MAGE-3. It is to be understood that when the epxression "nucleic acid molecule which codes for MAGE-3 TRAP" is used, all molecules are covered which yield this molecule upon expression. Any number of variations, such as those showing codon degeneracy within the coding region, or variation within the introns, are covered by the invention.

The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

(1) GENERAL INFORMATION:

(i) APPLICANTS: Gaugler, Béatrice; Van den Eynde, Benoît; van der Bruggen, Pierre; Boon-Falleur, Thierry

(ii) TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof

(iii) NUMBER OF SEQUENCES: 26

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Felfe & Lynch
(B) STREET: 805 Third Avenue
(C) CITY: New York City
(D) STATE: New York
(F) ZIP: 10022

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
(B) COMPUTER: IBM
(C) OPERATING SYSTEM: PC-DOS
(D) SOFTWARE: Wordperfect

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 08/037,230
(B) FILING DATE: 26-MARCH-1993

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: PCT/US92/04354
(B) FILING DATE: 22-MAY-1992

(viii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/807,043
(B) FILING DATE: 12-DECEMBER-1991

(ix) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/764,364
(B) FILING DATE: 23-SEPTEMBER-1991

(x) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/728,838
(b) FILING DATE: 9-JULY-1991

(xi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/705,702
(B) FILING DATE: 23-MAY-1991

(xii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Hanson, Norman D.
(B) REGISTRATION NUMBER: 30,946
(C) REFERENCE/DOCKET NUMBER: LUD 253.5

(xiii) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (212) 688-9200
(B) TELEFAX: (212) 838-3884

(2) INFORMATION FOR SEQUENCE ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 462 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```
ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT GAAGATCCTG  60
ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT CAGCCAATGA GCTTACTGTT 120
CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG 180
CTTGTGAATT TGTACCCTTT CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC 240
CCCCCTCCCA CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300
AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG CATGCATTGT 360
GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG CTAGCTTGCG ACTCTACTCT 420
TATCTTAACT TAGCTCGGCT TCCTGCTGGT ACCCTTTGTG CC                   462
```

(2) INFORMATION FOR SEQUENCE ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 675 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA GGT GGT   48
Met Ser Asp Asn Lys Lys Pro Asp Lys Ala His Ser Gly Ser Gly Gly
                5                  10                  15
GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG TAC TCC CTG GAA   96
Asp Gly Asp Gly Asn Arg Cys Asn Leu Leu His Arg Tyr Ser Leu Glu
            20                  25                  30
GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC TTC GCT GTT GTC ACA ACA  144
Glu Ile Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Val Val Thr Thr
        35                  40                  45
AGT TTT CTG GCG CTC CAG ATG TTC ATA GAC GCC CTT TAT GAG GAG CAG  192
Ser Phe Leu Ala Leu Gln Met Phe Ile Asp Ala Leu Tyr Glu Glu Gln
    50                  55                  60
TAT GAA AGG GAT GTG GCC TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC  240
Tyr Glu Arg Asp Val Ala Trp Ile Ala Arg Gln Ser Lys Arg Met Ser
65                  70                  75                  80
TCT GTC GAT GAG GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC  288
Ser Val Asp Glu Asp Glu Asp Asp Glu Asp Asp Glu Asp Asp Tyr Tyr
                85                  90                  95
GAC GAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT  336
Asp Asp Glu Asp Asp Asp Asp Asp Ala Phe Tyr Asp Asp Glu Asp Asp
            100                 105                 110
GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA GAT GAG  384
Glu Glu Glu Glu Leu Glu Asn Leu Met Asp Asp Glu Ser Glu Asp Glu
        115                 120                 125
GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA GCT GAG GAA ATG  432
Ala Glu Glu Glu Met Ser Val Glu Met Gly Ala Gly Ala Glu Glu Met
    130                 135                 140
GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT GGC CAT CAT TTA AGG AAG  480
Gly Ala Gly Ala Asn Cys Ala Cys Val Pro Gly His His Leu Arg Lys
145                 150                 155                 160
AAT GAA GTG AAG TGT AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC  528
Asn Glu Val Lys Cys Arg Met Ile Tyr Phe Phe His Asp Pro Asn Phe
                165                 170                 175
CTG GTG TCT ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT  576
Leu Val Ser Ile Pro Val Asn Pro Lys Glu Gln Met Glu Cys Arg Cys
            180                 185                 190
GAA AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG  624
Glu Asn Ala Asp Glu Glu Val Ala Met Glu Glu Glu Glu Glu Glu Glu
        195                 200                 210
GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT  672
Glu Glu Glu Glu Glu Glu Glu Met Gly Asn Pro Asp Gly Phe Ser Pro
220                 225                 230                 235

TAG                                                             675
```

(2) INFORMATION FOR SEQUENCE ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 228 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG TTGTTTTTTT 60
TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA ATTTGATTTT GTTCTAAAGT 120
TCATTATGCA AAGATGTCAC CAACAGACTT CTGACTGCAT GGTGAACTTT CATATGATAC 180
ATAGGATTAC ACTTGTACCT GTTAAAAATA AAAGTTTGAC TTGCATAC 228

(2) INFORMATION FOR SEQUENCE ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1365 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```
ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT        50
GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT       100
CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG       150
AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT       200
CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA       250
CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT       300
AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG       350
CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG       400
CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT       450
ACCCTTTGTG CC                                               462
ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA      504
GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG      546
TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC      588
TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC      630
ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC      672
TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG      714
GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC      756
GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT      798
GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA      840
GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA      882
GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT      924
GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT AGG ATG ATT      966
TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT ATA CCA GTG     1008
AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA AAT GCT GAT     1050
GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG GAG GAG     1092
GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT     1134
TAG                                                        1137
GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG      1187
TTGTTTTTTT TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA      1237
ATTTGATTTT GTTCTAAAGT TCATTATGCA AAGATGTCAC CAACAGACTT      1287
CTGACTGCAT GGTGAACTTT CATATGATAC ATAGGATTAC ACTTGTACCT      1337
GTTAAAAATA AAAGTTTGAC TTGCATAC                              1365
```

(2) INFORMATION FOR SEQUENCE ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4698 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```
ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT        50
GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT       100
CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG       150
AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT       200
CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA       250
CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT       300
AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG       350
CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG       400
CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT       450
ACCCTTTGTG CC                                               462
ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA      504
GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG      546
TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC      588
TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC      630
ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC      672
TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG      714
GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC      756
GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT      798
GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA      840
GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA      882
GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC T                916
GTGAGTAACC CGTGGTCTTT ACTCTAGATT CAGGTGGGGT GCATTCTTTA       966
CTCTTGCCCA CATCTGTAGT AAAGACCACA TTTTGGTTGG GGGTCATTGC      1016
TGGAGCCATT CCTGGCTCTC CTGTCCACGC CTATCCCCGC TCCTCCCATC      1066
CCCCACTCCT TGCTCCGCTC TCTTTCCTTT TCCCACCTTG CCTCTGGAGC      1116
TTCAGTCCAT CCTGCTCTGC TCCCTTTCCC CTTTGCTCTC CTTGCTCCCC      1166
TCCCCCTCGG CTCAACTTTT CGTGCCTTCT GCTCTCTGAT CCCCACCCTC      1216
TTCAGGCTTC CCCATTTGCT CCTCTCCCGA AACCCTCCCC TTCCTGTTCC      1266
CCTTTTCGCG CCTTTTCTTT CCTGCTCCCC TCCCCCTCCC TATTTACCTT      1316
TCACCAGCTT TGCTCTCCCT GCTCCCCTCC CCCTTTTGCA CCTTTTCTTT      1366
TCCTGCTCCC CTCCCCCTCC CCTCCCTGTT TACCCTTCAC CGCTTTTCCT      1416
CTACCTGCTT CCCTCCCCCT TGCTGCTCCC TCCCTATTTG CATTTTCGGG      1466
TGCTCCTCCC TCCCCCTCCC CCTCCCTCCC TATTTGCATT TTCGGGTGCT      1516
CCTCCCTCCC CCTCCCCAGG CCTTTTTTTT TTTTTTTTTT TTTTTTTTTT      1566
TTGGTTTTTC GAGACAGGGT TTCTCTTTGT ATCCCTGGCT GTCCTGGCAC      1616
TCACTCTGTA GACCAGGCTG GCCTCAAACT CAGAAATCTG CCTGCCTCTG      1666
CCTCCCAAAT GCTGGGATTA AAGGCTTGCA CCAGGACTGC CCCAGTGCAG      1716
GCCTTTCTTT TTTCTCCTCT CTGGTCTCCC TAATCCCTTT TCTGCATGTT      1766
AACTCCCCTT TTGGCACCTT TCCTTTACAG GACCCCCTCC CCCTCCCTGT      1816
TTCCCTTCCG GCACCCTTCC TAGCCCTGCT CTGTTCCCTC TCCCTGCTCC      1866
CCTCCCCCTC TTTGCTCGAC TTTTAGCAGC CTTACCTCTC CCTGCTTTCT      1916
GCCCCGTTCC CCTTTTTTGT GCCTTTCCTC CTGGCTCCCC TCCACCTTCC      1966
AGCTCACCTT TTTGTTTGTT TGGTTGTTTG GTTGTTTGGT TTGCTTTTTT      2016
TTTTTTTTTT GCACCTTGTT TTCCAAGATC CCCCTCCCCC TCCGGCTTCC      2066
CCTCTGTGTG CCTTTCCTGT TCCCTCCCCC TCGCTGGCTC CCCCTCCCTT      2116
TCTGCCTTTC CTGTCCCTGC TCCCTTCTCT GCTAACCTTT TAATGCCTTT      2166
CTTTTCTAGA CTCCCCCCTC CAGGCTTGCT GTTTGCTTCT GTGCACTTTT      2216
CCTGACCCTG CTCCCCTTCC CCTCCCAGCT CCCCCCTCTT TTCCCACCTC      2266
CCTTTCTCCA GCCTGTCACC CCTCCTTCTC TCCTCTCTGT TTCTCCCACT      2316
TCCTGCTTCC TTTACCCCTT CCCTCTCCCT ACTCTCCTCC CTGCCTGCTG      2366
GACTTCCTCT CCAGCCGCCC AGTTCCCTGC AGTCCTGGAG TCTTTCCTGC      2416
CTCTCTGTCC ATCACTTCCC CCTAGTTTCA CTTCCCTTTC ACTCTCCCCT      2466
ATGTGTCTCT CTTCCTATCT ATCCCTTCCT TTCTGTCCCC TCTCCTCTGT      2516
CCATCACCTC TCTCCTCCCT TCCCTTTCCT CTCTCTTCCA TTTTCTTCCA      2566
CCTGCTTCTT TACCCTGCCT CTCCCATTGC CCTCTTACCT TTATGCCCAT      2616
TCCATGTCCC CTCTCAATTC CCTGTCCCAT TGTGCTCCCT CACATCTTCC      2666
```

```
ATTTCCCTCT TTCTCCCTTA GCCTCTTCTT CCTCTTCTCT TGTATCTCCC      2716
TTCCCTTTGC TTCTCCCTCC TCCTTTCCCC TTCCCCTATG CCCTCTACTC      2766
TACTTGATCT TCTCTCCTCT CCACATACCC TTTTTCCTTT CCACCCTGCC      2816
CTTTGTCCCC AGACCCTACA GTATCCTGTG CACAGGAAGT GGGAGGTGCC      2866
ATCAACAACA AGGAGGCAAG AAACAGAGCA AAATCCCAAA ATCAGCAGGA      2916
AAGGCTGGAT GAAAATAAGG CCAGGTTCTG AGGACAGCTG GAATCTAGCC      2966
AAGTGGCTCC TATAACCCTA AGTACCAAGG GAGAAAGTGA TGGTGAAGTT      3016
CTTGATCCTT GCTGCTTCTT TTACATATGT TGGCACATCT TTCTCAAATG      3066
CAGGCCATGC TCCATGCTTG GCGCTTGCTC AGCGTGGTTA AGTAATGGGA      3116
GAATCTGAAA ACTAGGGGCC AGTGGTTTGT TTTGGGGACA AATTAGCACG      3166
TAGTGATATT TCCCCCTAAA AATTATAACA AACAGATTCA TGATTTGAGA      3216
TCCTTCTACA GGTGAGAAGT GGAAAAATTG TCACTATGAA GTTCTTTTTA      3266
GGCTAAAGAT ACTTGGAACC ATAGAAGCGT TGTTAAAATA CTGCTTTCTT      3316
TTGCTAAAAT ATTCTTTCTC ACATATTCAT ATTCTCCAG                  3355
 GT GTT CCT GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT      3396
AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT      3438
ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA      3480
AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA      3522
GAG GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC      3564
TTC TCA CCT TAG                                             3576
GCATGCAGGT ACTGGCTTCA CTAACCAACC ATTCCTAACA TATGCCTGTA      3626
GCTAAGAGCA TCTTTTTAAA AAATATTATT GGTAAACTAA ACAATTGTTA      3676
TCTTTTTACA TTAATAAGTA TTAAATTAAT CCAGTATACA GTTTTAAGAA      3726
CCCTAAGTTA AACAGAAGTC AATGATGTCT AGATGCCTGT TCTTTAGATT      3776
GTAGTGAGAC TACTTACTAC AGATGAGAAG TTGTTAGACT CGGGAGTAGA      3826
GACCAGTAAA AGATCATGCA GTGAAATGTG GCCATGGAAA TCGCATATTG      3876
TTCTTATAGT ACCTTTGAGA CAGCTGATAA CAGCTGACAA AAATAAGTGT      3926
TTCAAGAAAG ATCACACGCC ATGGTTCACA TGCAAATTAT TATTTTGTCG      3976
TTCTGATTTT TTTCATTTCT AGACCTGTGG TTTTAAAGAG ATGAAAATCT      4026
CTTAAAATTT CCTTCATCTT TAATTTTCCT TAACTTTAGT TTTTTTCACT      4076
TAGAATTCAA TTCAAATTCT TAATTCAATC TTAATTTTTA GATTTCTTAA      4126
AATGTTTTTT AAAAAAAATG CAAATCTCAT TTTTAAGAGA TGAAAGCAGA      4176
GTAACTGGGG GGCTTAGGGA ATCTGTAGGG TTGCGGTATA GCAATAGGGA      4226
GTTCTGGTCT CTGAGAAGCA GTCAGAGAGA ATGGAAAACC AGGCCCTTGC      4276
CAGTAGGTTA GTGAGGTTGA TATGATCAGA TTATGGACAC TCTCCAAATC      4326
ATAAATACTC TAACAGCTAA GGATCTCTGA GGGAAACACA ACAGGGAAAT      4376
ATTTTAGTTT CTCCTTGAGA AACAATGACA AGACATAAAA TTGGCAAGAA      4426
AGTCAGGAGT GTATTCTAAT AAGTGTTGCT TATCTCTTAT TTTCTTCTAC      4476
AGTTGCAAAG CCCAGAAGAA AGAAATGGAC AGCGGAAGAA GTGGTTGTTT      4526
TTTTTTCCCC TTCATTAATT TTCTAGTTTT TAGTAATCCA GAAAATTTGA      4576
TTTTGTTCTA AAGTTCATTA TGCAAAGATG TCACCAACAG ACTTCTGACT      4626
GCATGGTGAA CTTTCATATG ATACATAGGA TTACACTTGT ACCTGTTAAA      4676
AATAAAAGTT TGACTTGCAT AC                                    4698
```

(2) INFORMATION FOR SEQUENCE ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Leu Pro Tyr Leu Gly Trp Leu Val Phe
5

(2) INFORMATION FOR SEQUENCE ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2418 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

```
GGATCCAGGC CCTGCCAGGA AAAATATAAG GGCCCTGCGT GAGAACAGAG        50
GGGGTCATCC ACTGCATGAG AGTGGGGATG TCACAGAGTC CAGCCCACCC       100
TCCTGGTAGC ACTGAGAAGC CAGGGCTGTG CTTGCGGTCT GCACCCTGAG       150
GGCCCGTGGA TTCCTCTTCC TGGAGCTCCA GGAACCAGGC AGTGAGGCCT       200
TGGTCTGAGA CAGTATCCTC AGGTCACAGA GCAGAGGATG CACAGGGTGT       250
GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA       300
CAGGACACAT AGGACTCCAC AGAGTCTGGC CTCACCTCCC TACTGTCAGT       350
CCTGTAGAAT CGACCTCTGC TGGCCGGCTG TACCCTGAGT ACCCTCTCAC       400
TTCCTCCTTC AGGTTTTCAG GGGACAGGCC AACCCAGAGG ACAGGATTCC       450
CTGGAGGCCA CAGAGGAGCA CCAAGGAGAA GATCTGTAAG TAGGCCTTTG       500
TTAGAGTCTC CAAGGTTCAG TTCTCAGCTG AGGCCTCTCA CACACTCCCT       550
CTCTCCCCAG GCCTGTGGGT CTTCATTGCC CAGCTCCTGC CCACACTCCT       600
GCCTGCTGCC CTGACGAGAG TCATCATGTC TCTTGAGCAG AGGAGTCTGC       650
ACTGCAAGCC TGAGGAAGCC CTTGAGGCCC AACAAGAGGC CCTGGGCCTG       700
GTGTGTGTGC AGGCTGCCAC CTCCTCCTCC TCTCCTCTGG TCCTGGGCAC       750
CCTGGAGGAG GTGCCCACTG CTGGGTCAAC AGATCCTCCC CAGAGTCCTC       800
AGGGAGCCTC CGCCTTTCCC ACTACCATCA ACTTCACTCG ACAGAGGCAA       850
CCCAGTGAGG GTTCCAGCAG CCGTGAAGAG GAGGGGCCAA GCACCTCTTG       900
TATCCTGGAG TCCTTGTTCC GAGCAGTAAT CACTAAGAAG GTGGCTGATT       950
TGGTTGGTTT TCTGCTCCTC AAATATCGAG CCAGGGAGCC AGTCACAAAG      1000
GCAGAAATGC TGGAGAGTGT CATCAAAAAT TACAAGCACT GTTTTCCTGA      1050
GATCTTCGGC AAAGCCTCTG AGTCCTTGCA GCTGGTCTTT GGCATTGACG      1100
TGAAGGAAGC AGACCCCACC GGCCACTCCT ATGTCCTTGT CACCTGCCTA      1150
GGTCTCTCCT ATGATGGCCT GCTGGGTGAT AATCAGATCA TGCCCAAGAC      1200
AGGCTTCCTG ATAATTGTCC TGGTCATGAT TGCAATGGAG GGCGGCCATG      1250
CTCCTGAGGA GGAAATCTGG GAGGAGCTGA GTGTGATGGA GGTGTATGAT      1300
GGGAGGGAGC ACAGTGCCTA TGGGGAGCCC AGGAAGCTGC TCACCCAAGA      1350
TTTGGTGCAG GAAAAGTACC TGGAGTACGG CAGGTGCCGG ACAGTGATCC      1400
CGCACGCTAT GAGTTCCTGT GGGGTCCAAG GGCCCTCGCT GAAACCAGCT      1450
ATGTGAAAGT CCTTGAGTAT GTGATCAAGG TCAGTGCAAG AGTTCGCTTT      1500
TTCTTCCCAT CCCTGCGTGA AGCAGCTTTG AGAGAGGAGG AAGAGGGAGT      1550
CTGAGCATGA GTTGCAGCCA AGGCCAGTGG GAGGGGGACT GGGCCAGTGC      1600
ACCTTCCAGG GCCGCGTCCA GCAGCTTCCC CTGCCTCGTG TGACATGAGG      1650
CCCATTCTTC ACTCTGAAGA GAGCGGTCAG TGTTCTCAGT AGTAGGTTTC      1700
TGTTCTATTG GGTGACTTGG AGATTTATCT TTGTTCTCTT TTGGAATTGT      1750
TCAAATGTTT TTTTTTAAGG GATGGTTGAA TGAACTTCAG CATCCAAGTT      1800
TATGAATGAC AGCAGTCACA CAGTTCTGTG TATATAGTTT AAGGGTAAGA      1850
GTCTTGTGTT TTATTCAGAT TGGGAAATCC ATTCTATTTT GTGAATTGGG      1900
ATAATAACAG CAGTGGAATA AGTACTTAGA AATGTGAAAA ATGAGCAGTA      1950
AAATAGATGA GATAAAGAAC TAAAGAAATT AAGAGATAGT CAATTCTTGC      2000
CTTATACCTC AGTCTATTCT GTAAAATTTT TAAAGATATA TGCATACCTG      2050
GATTTCCTTG GCTTCTTTGA GAATGTAAGA GAAATTAAAT CTGAATAAAG      2100
AATTCTTCCT GTTCACTGGC TCTTTTCTTC TCCATGCACT GAGCATCTGC      2150
TTTTTGGAAG GCCCTGGGTT AGTAGTGGAG ATGCTAAGGT AAGCCAGACT      2200
CATACCCACC CATAGGGTCG TAGAGTCTAG GAGCTGCAGT CACGTAATCG      2250
AGGTGGCAAG ATGTCCTCTA AAGATGTAGG GAAAAGTGAG AGAGGGGTGA      2300
GGGTGTGGGG CTCCGGGTGA GAGTGGTGGA GTGTCAATGC CCTGAGCTGG      2350
GGCATTTTGG GCTTTGGGAA ACTGCAGTTC CTTCTGGGGG AGCTGATTGT      2400
AATGATCTTG GGTGGATCC                                       2418
```

(2) INFORMATION FOR SEQUENCE ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5724 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-1 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```
CCCGGGGCAC CACTGGCATC CCTCCCCCTA CCACCCCCAA TCCCTCCCTT    50
TACGCCACCC ATCCAAACAT CTTCACGCTC ACCCCCAGCC CAAGCCAGGC   100
AGAATCCGGT TCCACCCCTG CTCTCAACCC AGGGAAGCCC AGGTGCCCAG   150
ATGTGACGCC ACTGACTTGA GCATTAGTGG TTAGAGAGAA GCGAGGTTTT   200
CGGTCTGAGG GGCGGCTTGA GATCGGTGGA GGGAAGCGGG CCCAGCTCTG   250
TAAGGAGGCA AGGTGACATG CTGAGGGAGG ACTGAGGACC CACTTACCCC   300
AGATAGAGGA CCCCAAATAA TCCCTTCATG CCAGTCCTGG ACCATCTGGT   350
GGTGGACTTC TCAGGCTGGG CCACCCCCAG CCCCCTTGCT GCTTAAACCA   400
CTGGGGACTC GAAGTCAGAG CTCCGTGTGA TCAGGGAAGG GCTGCTTAGG   450
AGAGGGCAGC GTCCAGGCTC TGCCAGACAT CATGCTCAGG ATTCTCAAGG   500
AGGGCTGAGG GTCCCTAAGA CCCCACTCCC GTGACCCAAC CCCCACTCCA   550
ATGCTCACTC CCGTGACCCA ACCCCCTCTT CATTGTCATT CCAACCCCCA   600
CCCCACATCC CCCACCCCAT CCCTCAACCC TGATGCCCAT CCGCCCAGCC   650
ATTCCACCCT CACCCCCACC CCCACCCCCA CGCCCACTCC CACCCCCACC   700
CAGGCAGGAT CCGGTTCCCG CCAGGAAACA TCCGGGTGCC CGGATGTGAC   750
GCCACTGACT TGCGCATTGT GGGGCAGAGA GAAGCGAGGT TTCCATTCTG   800
AGGGACGGCG TAGAGTTCGG CCGAAGGAAC CTGACCCAGG CTCTGTGAGG   850
AGGCAAGGTG AGAGGCTGAG GGAGGACTGA GGACCCCGCC ACTCCAAATA   900
GAGAGCCCCA AATATTCCAG CCCCGCCCTT GCTGCCAGCC CTGGCCCACC   950
CGCGGGAAGA CGTCTCAGCC TGGGCTGCCC CCAGACCCCT GCTCCAAAAG  1000
CCTTGAGAGA CACCAGGTTC TTCTCCCCAA GCTCTGGAAT CAGAGGTTGC  1050
TGTGACCAGG GCAGGACTGG TTAGGAGAGG GCAGGGCACA GGCTCTGCCA  1100
GGCATCAAGA TCAGCACCCA AGAGGGAGGG CTGTGGGCCC CCAAGACTGC  1150
ACTCCAATCC CCACTCCCAC CCCATTCGCA TTCCCATTCC CCACCCAACC  1200
CCCATCTCCT CAGCTACACC TCCACCCCCA TCCCTACTCC TACTCCGTCA  1250
CCTGACCACC ACCCTCCAGC CCCAGCACCA GCCCCAACCC TTCTGCCACC  1300
TCACCCTCAC TGCCCCCAAC CCCACCCTCA TCTCTCTCAT GTGCCCCACT  1350
CCCATCGCCT CCCCCATTCT GGCAGAATCC GGTTTGCCCC TGCTCTCAAC  1400
CCAGGGAAGC CCTGGTAGGC CCGATGTGAA ACCACTGACT TGAACCTCAC  1450
AGATCTGAGA GAAGCCAGGT TCATTTAATG GTTCTGAGGG GCGGCTTGAG  1500
ATCCACTGAG GGGAGTGGTT TTAGGCTCTG TGAGGAGGCA AGGTGAGATG  1550
CTGAGGGAGG ACTGAGGAGG CACACACCCC AGGTAGATGG CCCCAAAATG  1600
ATCCAGTACC ACCCCTGCTG CCAGCCCTGG ACCACCCGGC CAGGACAGAT  1650
GTCTCAGCTG GACCACCCCC CGTCCCGTCC CACTGCCACT TAACCCACAG  1700
GGCAATCTGT AGTCATAGCT TATGTGACCG GGGCAGGGTT GGTCAGGAGA  1750
GGCAGGGCCC AGGCATCAAG GTCCAGCATC CGCCCGGCAT TAGGGTCAGG  1800
ACCCTGGGAG GGAACTGAGG GTTCCCCACC CACACCTGTC TCCTCATCTC  1850
CACCGCCACC CCACTCACAT TCCCATACCT ACCCCCTACC CCCAACCTCA  1900
TCTTGTCAGA ATCCCTGCTG TCAACCCACG GAAGCCACGG GAATGGCGGC  1950
CAGGCACTCG GATCTTGACG TCCCCATCCA GGGTCTGATG GAGGGAAGGG  2000
GCTTGAACAG GGCCTCAGGG GAGCAGAGGG AGGGCCCTAC TGCGAGATGA  2050
GGGAGGCCTC AGAGGACCCA GCACCCTAGG ACACCGCACC CCTGTCTGAG  2100
ACTGAGGCTG CCACTTCTGG CCTCAAGAAT CAGAACGATG GGGACTCAGA  2150
TTGCATGGGG GTGGGACCCA GGCCTGCAAG GCTTACGCGG AGGAAGAGGA  2200
GGGAGGACTC AGGGGACCTT GGAATCCAGA TCAGTGTGGA CCTCGGCCCT  2250
GAGAGGTCCA GGGCACGGTG GCCACATATG GCCCATATTT CCTGCATCTT  2300
TGAGGTGACA GGACAGAGCT GTGGTCTGAG AAGTGGGGCC TCAGGTCAAC  2350
AGAGGGAGGA GTTCCAGGAT CCATATGGCC CAAGATGTGC CCCCTTCATG  2400
AGGACTGGGG ATATCCCCGG CTCAGAAAGA AGGGACTCCA CACAGTCTGG  2450
CTGTCCCCTT TTAGTAGCTC TAGGGGGACC AGATCAGGGA TGGCGGTATG  2500
TTCCATTCTC ACTTGTACCA CAGGCAGGAA GTTGGGGGGC CCTCAGGGAG  2550
ATGGGGTCTT GGGGTAAAGG GGGGATGTCT ACTCATGTCA GGGAATTGGG  2600
GGTTGAGGAA GCACAGGCGC TGGCAGGAAT AAAGATGAGT GAGACAGACA  2650
AGGCTATTGG AATCCACACC CCAGAACCAA AGGGGTCAGC CCTGGACACC  2700
```

TCACCCAGGA TGTGGCTTCT TTTTCACTCC TGTTTCCAGA TCTGGGGCAG 2750
GTGAGGACCT CATTCTCAGA GGGTGACTCA GGTCAACGTA GGGACCCCCA 2800
TCTGGTCTAA AGACAGAGCG GTCCCAGGAT CTGCCATGCG TTCGGGTGAG 2850
GAACATGAGG GAGGACTGAG GGTACCCCAG GACCAGAACA CTGAGGGAGA 2900
CTGCACAGAA ATCAGCCCTG CCCCTGCTGT CACCCCAGAG AGCATGGGCT 2950
GGGCCGTCTG CCGAGGTCCT TCCGTTATCC TGGGATCATT GATGTCAGGG 3000
ACGGGGAGGC CTTGGTCTGA GAAGGCTGCG CTCAGGTCAG TAGAGGGAGC 3050
GTCCCAGGCC CTGCCAGGAG TCAAGGTGAG GACCAAGCGG GCACCTCACC 3150
CAGGACACAT TAATTCCAAT GAATTTTGAT ATCTCTTGCT GCCCTTCCCC 3200
AAGGACCTAG GCACGTGTGG CCAGATGTTT GTCCCCTCCT GTCCTTCCAT 3250
TCCTTATCAT GGATGTGAAC TCTTGATTTG GATTTCTCAG ACCAGCAAAA 3300
GGGCAGGATC CAGGCCCTGC CAGGAAAAAT ATAAGGGCCC TGCGTGAGAA 3350
CAGAGGGGGT CATCCACTGC ATGAGAGTGG GGATGTCACA GAGTCCAGCC 3400
CACCCTCCTG GTAGCACTGA GAAGCCAGGG CTGTGCTTGC GGTCTGCACC 3450
CTGAGGGCCC GTGGATTCCT CTTCCTGGAG CTCCAGGAAC CAGGCAGTGA 3500
GGCCTTGGTC TGAGACAGTA TCCTCAGGTC ACAGAGCAGA GGATGCACAG 3550
GGTGTGCCAG CAGTGAATGT TTGCCCTGAA TGCACACCAA GGGCCCCACC 3600
TGCCACAGGA CACATAGGAC TCCACAGAGT CTGGCCTCAC CTCCCTACTG 3650
TCAGTCCTGT AGAATCGACC TCTGCTGGCC GGCTGTACCC TGAGTACCCT 3700
CTCACTTCCT CCTTCAGGTT TTCAGGGGAC AGGCCAACCC AGAGGACAGG 3750
ATTCCCTGGA GGCCACAGAG GAGCACCAAG GAGAAGATCT GTAAGTAGGC 3800
CTTTGTTAGA GTCTCCAAGG TTCAGTTCTC AGCTGAGGCC TCTCACACAC 3850
TCCCTCTCTC CCCAGGCCTG TGGGTCTTCA TTGCCCAGCT CCTGCCCACA 3900
CTCCTGCCTG CTGCCCTGAC GAGAGTCATC 3930
ATG TCT CTT GAG CAG AGG AGT CTG CAC TGC AAG CCT GAG GAA 3972
GCC CTT GAG GCC CAA CAA GAG GCC CTG GGC CTG GTG TGT GTG 4014
CAG GCT GCC ACC TCC TCC TCC TCT CCT CTG GTC CTG GGC ACC 4056
CTG GAG GAG GTG CCC ACT GCT GGG TCA ACA GAT CCT CCC CAG 4098
AGT CCT CAG GGA GCC TCC GCC TTT CCC ACT ACC ATC AAC TTC 4140
ACT CGA CAG AGG CAA CCC AGT GAG GGT TCC AGC AGC CGT GAA 4182
GAG GAG GGG CCA AGC ACC TCT TGT ATC CTG GAG TCC TTG TTC 4224
CGA GCA GTA ATC ACT AAG AAG GTG GCT GAT TTG GTT GGT TTT 4266
CTG CTC CTC AAA TAT CGA GCC AGG GAG CCA GTC ACA AAG GCA 4308
GAA ATG CTG GAG AGT GTC ATC AAA AAT TAC AAG CAC TGT TTT 4350
CCT GAG ATC TTC GGC AAA GCC TCT GAG TCC TTG CAG CTG GTC 4392
TTT GGC ATT GAC GTG AAG GAA GCA GAC CCC ACC GGC CAC TCC 4434
TAT GTC CTT GTC ACC TGC CTA GGT CTC TCC TAT GAT GGC CTG 4476
CTG GGT GAT AAT CAG ATC ATG CCC AAG ACA GGC TTC CTG ATA 4518
ATT GTC CTG GTC ATG ATT GCA ATG GAG GGC GGC CAT GCT CCT 4560
GAG GAG GAA ATC TGG GAG GAG CTG AGT GTG ATG GAG GTG TAT 4602
GAT GGG AGG GAG CAC AGT GCC TAT GGG GAG CCC AGG AAG CTG 4644
CTC ACC CAA GAT TTG GTG CAG GAA AAG TAC CTG GAG TAC GGC 4686
AGG TGC CGG ACA GTG ATC CCG CAC GCT ATG AGT TCC TGT GGG 4728
GTC CAA GGG CCC TCG CTG AAA CCA GCT ATG TGA 4761
AAGTCCTTGA GTATGTGATC AAGGTCAGTG CAAGAGTTC 4800
GCTTTTTCTT CCCATCCCTG CGTGAAGCAG CTTTGAGAGA GGAGGAAGAG 4850
GGAGTCTGAG CATGAGTTGC AGCCAAGGCC AGTGGGAGGG GGACTGGGCC 4900
AGTGCACCTT CCAGGGCCGC GTCCAGCAGC TTCCCCTGCC TCGTGTGACA 4950
TGAGGCCCAT TCTTCACTCT GAAGAGAGCG GTCAGTGTTC TCAGTAGTAG 5000
GTTTCTGTTC TATTGGGTGA CTTGGAGATT TATCTTTGTT CTCTTTTGGA 5050
ATTGTTCAAA TGTTTTTTTT TAAGGGATGG TTGAATGAAC TTCAGCATCC 5100
AAGTTTATGA ATGACAGCAG TCACACAGTT CTGTGTATAT AGTTTAAGGG 5150
TAAGAGTCTT GTGTTTTATT CAGATTGGGA AATCCATTCT ATTTTGTGAA 5200
TTGGGATAAT AACAGCAGTG GAATAAGTAC TTAGAAATGT GAAAAATGAG 5250
CAGTAAAATA GATGAGATAA AGAACTAAAG AAATTAAGAG ATAGTCAATT 5300
CTTGCCTTAT ACCTCAGTCT ATTCTGTAAA ATTTTTAAAG ATATATGCAT 5350
ACCTGGATTT CCTTGGCTTC TTTGAGAATG TAAGAGAAAT TAAATCTGAA 5400
TAAAGAATTC TTCCTGTTCA CTGGCTCTTT TCTTCTCCAT GCACTGAGCA 5450
TCTGCTTTTT GGAAGGCCCT GGGTTAGTAG TGGAGATGCT AAGGTAAGCC 5500
AGACTCATAC CCACCCATAG GGTCGTAGAG TCTAGGAGCT GCAGTCACGT 5550
AATCGAGGTG GCAAGATGTC CTCTAAAGAT GTAGGGAAAA GTGAGAGAGG 5600
GGTGAGGGTG TGGGGCTCCG GGTGAGAGTG GTGGAGTGTC AATGCCCTGA 5650
GCTGGGGCAT TTTGGGCTTT GGGAAACTGC AGTTCCTTCT GGGGGAGCTG 5700
ATTGTAATGA TCTTGGGTGG ATCC 5724

(2) INFORMATION FOR SEQUENCE ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4157 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-2 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

```
CCCATCCAGA TCCCCATCCG GGCAGAATCC GGTTCCACCC TTGCCGTGAA              50
CCCAGGGAAG TCACGGGCCC GGATGTGACG CCACTGACTT GCACATTGGA             100
GGTCAGAGGA CAGCGAGATT CTCGCCCTGA GCAACGGCCT GACGTCGGCG             150
GAGGGAAGCA GGCGCAGGCT CCGTGAGGAG GCAAGGTAAG ACGCCGAGGG             200
AGGACTGAGG CGGGCCTCAC CCCAGACAGA GGGCCCCCAA TTAATCCAGC             250
GCTGCCTCTG CTGCCGGGCC TGGACCACCC TGCAGGGGAA GACTTCTCAG             300
GCTCAGTCGC CACCACCTCA CCCCGCCACC CCCCGCCGCT TTAACCGCAG             350
GGAACTCTGG CGTAAGAGCT TTGTGTGACC AGGGCAGGGC TGGTTAGAAG             400
TGCTCAGGGC CCAGACTCAG CCAGGAATCA AGGTCAGGAC CCCAAGAGGG             450
GACTGAGGGC AACCCACCCC CTACCCTCAC TACCAATCCC ATCCCCCAAC             500
ACCAACCCCA CCCCCATCCC TCAAACACCA ACCCCACCCC CAAACCCCAT             550
TCCCATCTCC TCCCCCACCA CCATCCTGGC AGAATCCGGC TTTGCCCCTG             600
CAATCAACCC ACGGAAGCTC CGGGAATGGC GGCCAAGCAC GCGGATCCTG             650
ACGTTCACAT GTACGGCTAA GGGAGGGAAG GGGTTGGGTC TCGTGAGTAT             700
GGCCTTTGGG ATGCAGAGGA AGGGCCCAGG CCTCCTGGAA GACAGTGGAG             750
TCCTTAGGGG ACCCAGCATG CCAGGACAGG GGGCCCACTG TACCCCTGTC             800
TCAAACTGAG CCACCTTTTC ATTCAGCCGA GGGAATCCTA GGGATGCAGA             850
CCCACTTCAG GGGGTTGGGG CCCAGCCTGC GAGGAGTCAA GGGGAGGAAG             900
AAGAGGGAGG ACTGAGGGGA CCTTGGAGTC CAGATCAGTG GCAACCTTGG             950
GCTGGGGGAT CCTGGGCACA GTGGCCGAAT GTGCCCCGTG CTCATTGCAC            1000
CTTCAGGGTG ACAGAGAGTT GAGGGCTGTG GTCTGAGGGC TGGGACTTCA            1050
GGTCAGCAGA GGGAGGAATC CCAGGATCTG CCGGACCCAA GGTGTGCCCC            1100
CTTCATGAGG ACTCCCCATA CCCCCGGCCC AGAAAGAAGG GATGCCACAG            1150
AGTCTGGAAG TAAATTGTTC TTAGCTCTGG GGGAACCTGA TCAGGGATGG            1200
CCCTAAGTGA CAATCTCATT TGTACCACAG GCAGGAGGTT GGGGAACCCT            1250
CAGGGAGATA AGGTGTTGGT GTAAAGAGGA GCTGTCTGCT CATTTCAGGG            1300
GGTTCCCCCT TGAGAAAGGG CAGTCCCTGG CAGGAGTAAA GATGAGTAAC            1350
CCACAGGAGG CCATCATAAC GTTCACCCTA GAACCAAAGG GGTCAGCCCT            1400
GGACAACGCA CGTGGGGTAA CAGGATGTGG CCCCTCCTCA CTTGTCTTTC            1450
CAGATCTCAG GGAGTTGATG ACCTTGTTTT CAGAAGGTGA CTCAGTCAAC            1500
ACAGGGGCCC CTCTGGTCGA CAGATGCAGT GGTTCTAGGA TCTGCCAAGC            1550
ATCCAGGTGG AGAGCCTGAG GTAGGATTGA GGGTACCCCT GGGCCAGAAT            1600
GCAGCAAGGG GGCCCCATAG AAATCTGCCC TGCCCCTGCG GTTACTTCAG            1650
AGACCCTGGG CAGGGCTGTC AGCTGAAGTC CCTCCATTAT CTGGGATCTT            1700
TGATGTCAGG GAAGGGGAGG CCTTGGTCTG AAGGGGCTGG AGTCAGGTCA            1750
GTAGAGGGAG GGTCTCAGGC CCTGCCAGGA GTGGACGTGA GGACCAAGCG            1800
GACTCGTCAC CCAGGACACC TGGACTCCAA TGAATTTGAC ATCTCTCGTT            1850
GTCCTTCGCG GAGGACCTGG TCACGTATGG CCAGATGTGG GTCCCCTCTA            1900
TCTCCTTCTG TACCATATCA GGGATGTGAG TTCTTGACAT GAGAGATTCT            1950
CAAGCCAGCA AAAGGGTGGG ATTAGGCCCT ACAAGGAGAA AGGTGAGGGC           2000
CCTGAGTGAG CACAGAGGGG ACCCTCCACC CAAGTAGAGT GGGGACCTCA           2050
CGGAGTCTGG CCAACCCTGC TGAGACTTCT GGGAATCCGT GGCTGTGCTT           2100
GCAGTCTGCA CACTGAAGGC CCGTGCATTC CTCTCCCAGG AATCAGGAGC           2150
TCCAGGAACC AGGCAGTGAG GCCTTGGTCT GAGTCAGTGC CTCAGGTCAC           2200
AGAGCAGAGG GGACGCAGAC AGTGCCAACA CTGAAGGTTT GCCTGGAATG           2250
CACACCAAGG GCCCCACCCG CCCAGAACAA ATGGGACTCC AGAGGGCCTG           2300
GCCTCACCCT CCCTATTCTC AGTCCTGCAG CCTGAGCATG TGCTGGCCGG           2350
CTGTACCCTG AGGTGCCCTC CCACTTCCTC CTTCAGGTTC TGAGGGGGAC           2400
AGGCTGACAA GTAGGACCCG AGGCACTGGA GGAGCATTGA AGGAGAAGAT           2450
CTGTAAGTAA GCCTTTGTCA GAGCCTCCAA GGTTCAGTTC AGTTCTCACC           2500
TAAGGCCTCA CACACGCTCC TTCTCTCCCC AGGCCTGTGG GTCTTCATTG           2550
CCCAGCTCCT GCCCGCACTC CTGCCTGCTG CCCTGACCAG AGTCATC              2597
ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA           2639
GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG GTG GGT GCG           2681
CAG GCT CCT GCT ACT GAG GAG CAG CAG ACC GCT TCT TCC TCT           2723
```

TCT ACT CTA GTG GAA GTT ACC CTG GGG GAG GTG CCT GCT GCC 2765
GAC TCA CCG AGT CCT CCC CAC AGT CCT CAG GGA GCC TCC AGC 2807
TTC TCG ACT ACC ATC AAC TAC ACT CTT TGG AGA CAA TCC GAT 2849
GAG GGC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGA ATG TTT 2891
CCC GAC CTG GAG TCC GAG TTC CAA GCA GCA ATC AGT AGG AAG 2933
ATG GTT GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC 2975
AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGT GTC CTC 3017
AGA AAT TGC CAG GAC TTC TTT CCC GTG ATC TTC AGC AAA GCC 3059
TCC GAG TAC TTG CAG CTG GTC TTT GGC ATC GAG GTG GTG GAA 3101
GTG GTC CCC ATC AGC CAC TTG TAC ATC CTT GTC ACC TGC CTG 3143
GGC CTC TCC TAC GAT GGC CTG CTG GGC GAC AAT CAG GTC ATG 3185
CCC AAG ACA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA 3227
ATA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG 3269
CTG AGT ATG TTG GAG GTG TTT GAG GGG AGG GAG GAC AGT GTC 3311
TTC GCA CAT CCC AGG AAG CTG CTC ATG CAA GAT CTG GTG CAG 3353
GAA AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT 3395
GCA TGC TAC GAG TTC CTG TGG GGT CCA AGG GCC CTC ATT GAA 3437
ACC AGC TAT GTG AAA GTC CTG CAC CAT ACA CTA AAG ATC GGT 3479
GGA GAA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAA CGG GCT 3521
TTG AGA GAG GGA GAA GAG TGA 3542
GTCTCAGCAC ATGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT 3592
GCACCTTCCA GGGCCCCATC CATTAGCTTC CACTGCCTCG TGTGATATGA 3642
GGCCCATTCC TGCCTCTTTG AAGAGAGCAG TCAGCATTCT TAGCAGTGAG 3692
TTTCTGTTCT GTTGGATGAC TTTGAGATTT ATCTTTCTTT CCTGTTGGAA 3742
TTGTTCAAAT GTTCCTTTTA ACAAATGGTT GGATGAACTT CAGCATCCAA 3792
GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGGG 3842
TAAGAGTCCT GTTTTTTATT CAGATTGGGA AATCCATTCC ATTTTGTGAG 3892
TTGTCACATA ATAACAGCAG TGGAATATGT ATTTGCCTAT ATTGTGAACG 3942
AATTAGCAGT AAAATACATG ATACAAGGAA CTCAAAAGAT AGTTAATTCT 3992
TGCCTTATAC CTCAGTCTAT TATGTAAAAT TAAAAATATG TGTATGTTTT 4042
TGCTTCTTTG AGAATGCAAA AGAAATTAAA TCTGAATAAA TTCTTCCTGT 4092
TCACTGGCTC ATTTCTTTAC CATTCACTCA GCATCTGCTC TGTGGAAGGC 4142
CCTGGTAGTA GTGGG 4157

(2) INFORMATION FOR SEQUENCE ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 662 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(ix) FEATURE:

(A) NAME/KEY: MAGE-21 gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```
GGATCCCCAT GGATCCAGGA AGAATCCAGT TCCACCCCTG CTGTGAACCC     50
AGGGAAGTCA CGGGGCCGGA TGTGACGCCA CTGACTTGCG CGTTGGAGGT    100
CAGAGAACAG CGAGATTCTC GCCCTGAGCA ACGGCCTGAC GTCGGCGGAG    150
GGAAGCAGGC GCAGGCTCCG TGAGGAGGCA AGGTAAGATG CCGAGGGAGG    200
ACTGAGGCGG GCCTCACCCC AGACAGAGGG CCCCCAATAA TCCAGCGCTG    250
CCTCTGCTGC CAGGCCTGGA CCACCCTGCA GGGGAAGACT TCTCAGGCTC    300
AGTCGCCACC ACCTCACCCC GCCACCCCCC GCCGCTTTAA CCGCAGGGAA    350
CTCTGGTGTA AGAGCTTTGT GTGACCAGGG CAGGGCTGGT TAGAAGTGCT    400
CAGGGCCCAG ACTCAGCCAG GAATCAAGGT CAGGACCCCA AGAGGGGACT    450
GAGGGTAACC CCCCCGCACC CCCACCACCA TTCCCATCCC CCAACACCAA    500
CCCCACCCCC ATCCCCCAAC ACCAAACCCA CCACCATCGC TCAAACATCA    550
ACGGCACCCC CAAACCCCGA TTCCCATCCC CACCCATCCT GGCAGAATCG    600
GAGCTTTGCC CCTGCAATCA ACCCACGGAA GCTCCGGGAA TGGCGGCCAA    650
GCACGCGGAT CC                                             662
```

(2) INFORMATION FOR SEQUENCE ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1640 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA to mRNA
(ix) FEATURE:
(A) NAME/KEY: cDNA MAGE-3
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

```
GCCGCGAGGG AAGCCGGCCC AGGCTCGGTG AGGAGGCAAG GTTCTGAGGG              50
GACAGGCTGA CCTGGAGGAC CAGAGGCCCC CGGAGGAGCA CTGAAGGAGA             100
AGATCTGCCA GTGGGTCTCC ATTGCCCAGC TCCTGCCCAC ACTCCCGCCT             150
GTTGCCCTGA CCAGAGTCAT C                                            171
ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA             213
GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG GTG GGT GCG             255
CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCC TCC TCT             297
TCT ACT CTA GTT GAA GTC ACC CTG GGG GAG GTG CCT GCT GCC             339
GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA GCC TCC AGC             381
CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC CAA TCC TAT             423
GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGC ACC TTC             465
CCT GAC CTG GAG TCC GAG TTC CAA GCA GCA CTC AGT AGG AAG             507
GTG GCC GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC             549
AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GGG AGT GTC GTC             591
GGA AAT TGG CAG TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT             633
TCC AGT TCC TTG CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA             675
GTG GAC CCC ATC GGC CAC TTG TAC ATC TTT GCC ACC TGC CTG             717
GGC CTC TCC TAC GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG             759
CCC AAG GCA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA             801
AGA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG             843
CTG AGT GTG TTA GAG GTG TTT GAG GGG AGG GAA GAC AGT ATG             885
TTG GGG GAT CCC AAG AAG CTG CTC ACC CAA CAT TTC GTG CAG             927
GAA AAC TAC CTG GAG TAC CGG CAG GTC CCC GGC AGT GAT CCT             969
GCA TGT TAT GAA TTC CTG TGG GGT CCA AGG GCC CTC GTT GAA            1011
ACC AGC TAT GTG AAA GTC CTG CAC CAT ATG GTA AAG ATC AGT            1053
GGA GGA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAG TGG GTT            1095
TTG AGA GAG GGG GAA GAG TGA                                       1116
GTCTGAGCAC GAGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT            1166
GCACCTTCCG GGGCCGCATC CCTTAGTTTC CACTGCCTCC TGTGACGTGA            1216
GGCCCATTCT TCACTCTTTG AAGCGAGCAG TCAGCATTCT TAGTAGTGGG            1266
TTTCTGTTCT GTTGGATGAC TTTGAGATTA TTCTTTGTTT CCTGTTGGAG            1316
TTGTTCAAAT GTTCCTTTTA ACGGATGGTT GAATGAGCGT CAGCATCCAG            1366
GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGAG            1416
TAAGAGTCTT GttTTTTACT CAAATTgGGA AATCCATTCC ATTTTGTGAA            1466
TTGTGACATA ATAATAGCAG TGGTAAAAGT ATTTGCTTAA AATTGTGAGC            1516
GAATTAGCAA TAACATACAT GAGATAACTC AAGAAATCAA AAGATAGTTG            1566
ATTCTTGCCT TGTACCTCAA TCTATTCTGT AAAATTAAAC AAATATGCAA            1616
ACCAGGATTT CCTTGACTTC TTTG                                        1640
```

(2) INFORMATION FOR SEQUENCE ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 943 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-31 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

```
GGATCCTCCA CCCCAGTAGA GTGGGGACCT CACAGAGTCT GGCCAACCCT      50
CCTGACAGTT CTGGGAATCC GTGGCTGCGT TTGCTGTCTG CACATTGGGG     100
GCCCGTGGAT TCCTCTCCCA GGAATCAGGA GCTCCAGGAA CAAGGCAGTG     150
AGGACTTGGT CTGAGGCAGT GTCCTCAGGT CACAGAGTAG AGGGGgCTCA     200
GATAGTGCCA ACGGTGAAGG TTTGCCTTGG ATTCAAACCA AGGGCCCCAC     250
CTGCCCCAGA ACACATGGAC TCCAGAGCGC CTGGCCTCAC CCTCAATACT     300
TTCAGTCCTG CAGCCTCAGC ATGCGCTGGC CGGATGTACC CTGAGGTGCC     350
CTCTCACTTC CTCCTTCAGG TTCTGAGGGG ACAGGCTGAC CTGGAGGACC     400
AGAGGCCCCC GGAGGAGCAC TGAAGGAGAA GATCTGTAAG TAAGCCTTTG     450
TTAGAGCCTC CAAGGTTCCA TTCAGTACTC AGCTGAGGTC TCTCACATGC     500
TCCCTCTCTC CCCAGGCCAG TGGGTCTCCA TTGCCCAGCT CCTGCCCACA     550
CTCCCGCCTG TTGCCCTGAC CAGAGTCATC                           580
ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG CCT GAA GAA     622
GGC CTT GAG GCC CGA GGA GAg GCC CTG GGC CTG GTG GGT GCG     664
CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCC TCC TCT     706
TCT AGT GTA GTT GAA GTC ACC CTG GGG GAG GTG CCT GCT GCC     748
GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA GCC TCC AGC     790
CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC CAA TCC TAT     832
GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGC ACC TTC     874
CCT GAC CTG GAG TCT GAG TTC CAA GCA GCA CTC AGT AGG AAG     916
GTG GCC AAG TTG GTT CAT TTT CTG CTC                        943
```

(2) INFORMATION FOR SEQUENCE ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2531 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-4 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

```
GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG              50
GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC             100
TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG             150
GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT             200
TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT             250
GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA             300
CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT             350
CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA             400
CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC             450
TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT             500
TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC             550
TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG             600
CCTGCTGCCC TGACCAGAGT CATC                                         624
ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA             666
GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCA             708
CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC             750
TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT             792
GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT             834
GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC             876
AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC             918
TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC             960
AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA            1002
GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC            1044
ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA            1086
GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG            1128
GAA GTG GAC CCC GCC AGC AAC ACC TAC ACC CTT GTC ACC TGC            1170
CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC            1212
TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT            1254
GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG            1296
GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT            1338
GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG            1380
CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT            1422
CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT            1464
GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC            1506
AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA            1548
GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA                           1578
GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC            1628
ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC            1678
CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT            1728
TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT            1778
GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT            1828
TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG            1878
AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG            1928
GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT            1978
GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA            2028
GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG            2078
CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA            2128
ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC            2178
AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA            2228
GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT            2278
CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT            2328
GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA            2378
AACTGCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC            2428
AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC            2478
```

TCTGAGCAGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528
GGG 2531

(2) INFORMATION FOR SEQUENCE ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2531 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-41 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG 50
GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC 100
TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG 150
GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT 200
TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT 250
GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300
CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT 350
CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA 400
CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC 450
TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT 500
TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC 550
TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG 600
CCTGCTGCCC TGAGCAGAGT CATC 624
ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 666
GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCG 708
CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC 750
TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT 792
GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT 834
GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC 876
AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC 918
TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC 960
AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA 1002
GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC 1044
ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA 1086
GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG 1128
GAA GTG GAC CCC ACC AGC AAC ACC TAC ACC CTT GTC ACC TGC 1170
CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC 1212
TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT 1254
GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG 1296
GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT 1338
GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG 1380
CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT 1422
CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT 1464
GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC 1506
AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA 1548
GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA 1578
GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC 1628
ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC 1678
CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT 1728
TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT 1778
GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT 1828
TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG 1878
AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG 1928
GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT 1978
GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA 2028
GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG 2078
CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA 2128
ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC 2178
AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA 2228
GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT 2278
CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT 2328
GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA 2378
AACTCCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC 2428

AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC 2478
TCTGAGCGGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528
GGG 2531

(2) INFORMATION FOR SEQUENCE ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1068 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(ix) FEATURE:

(A) NAME/KEY: cDNA MAGE-4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

```
  G GGG CCA AGC ACC TCG CCT GAC GCA GAG TCC TTG TTC CGA        40
GAA GCA CTC AGT AAC AAG GTG GAT GAG TTG GCT CAT TTT CTG        82
CTC CGC AAG TAT CGA GCC AAG GAG CTG GTC ACA AAG GCA GAA       124
ATG CTG GAG AGA GTC ATC AAA AAT TAC AAG CGC TGC TTT CCT       166
GTG ATC TTC GGC AAA GCC TCC GAG TCC CTG AAG ATG ATC TTT       208
GGC ATT GAC GTG AAG GAA GTG GAC CCC GCC AGC AAC ACC TAC       250
ACC CTT GTC ACC TGC CTG GGC CTT TCC TAT GAT GGC CTG CTG       292
GGT AAT AAT CAG ATC TTT CCC AAG ACA GGC CTT CTG ATA ATC       334
GTC CTG GGC ACA ATT GCA ATG GAG GGC GAC AGC GCC TCT GAG       376
GAG GAA ATC TGG GAG GAG CTG GGT GTG ATG GGG GTG TAT GAT       418
GGG AGG GAG CAC ACT GTC TAT GGG GAG CCC AGG AAA CTG CTC       460
ACC CAA GAT TGG GTG CAG GAA AAC TAC CTG GAG TAC CGG CAG       502
GTA CCC GGC AGT AAT CCT GCG CGC TAT GAG TTC CTG TGG GGT       544
CCA AGG GCT CTG GCT GAA ACC AGC TAT GTG AAA GTC CTG GAG       586
CAT GTG GTC AGG GTC AAT GCA AGA GTT CGC ATT GCC TAC CCA       628
TCC CTG CGT GAA GCA GCT TTG TTA GAG GAG GAA GAG GGA GTC       670
TGAGCATGAG TTGCAGCCAG GGCTGTGGGG AAGGGGCAGG GCTGGGCCAG        720
TGCATCTAAC AGCCCTGTGC AGCAGCTTCC CTTGCCTCGT GTAACATGAG        770
GCCCATTCTT CACTCTGTTT GAAGAAAATA GTCAGTGTTC TTAGTAGTGG        820
GTTTCTATTT TGTTGGATGA CTTGGAGATT TATCTCTGTT TCCTTTTACA        870
ATTGTTGAAA TGTTCCTTTT AATGGATGGT TGAATTAACT TCAGCATCCA        920
AGTTTATGAA TCGTAGTTAA CGTATATTGC TGTTAATATA GTTTAGGAGT        970
AAGAGTCTTG TTTTTTATTC AGATTGGGAA ATCCGTTCTA TTTTGTGAAT       1020
TTGGGACATA ATAACAGCAG TGGAGTAAGT ATTTAGAAGT GTGAATTC         1068
```

(2) INFORMATION FOR SEQUENCE ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2226 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-5 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50
GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100
TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150
GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200
TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250
TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300
GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350
TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400
CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450
GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500
ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT TTTTAGCTGA 550
GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600
AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644
ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 684
CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 728
GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 770
TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 812
AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 854
CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 896
TGG CTG ACT TGA 908
TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCTGGT CACAAAGGCA 958
GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1008
CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1058
AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1108
CTCCTATGAT GGCCTGCTGG TTGATAATAA TCAGATCATG CCCAAGACGG 1158
GCCTCCTGAT AATCGTCTTG GGCATGATTG CAATGGAGGG CAAATGCGTC 1208
CCTGAGGAGA AAATCTGGGA GGAGCTGAGT GTGATGAAGG TGTATGTTGG 1258
GAGGGAGCAC AGTGTCTGTG GGGAGCCCAG GAAGCTGCTC ACCCAAGATT 1308
TGGTGCAGGA AAACTACCTG GAGTACCGGC AGGTGCCCAG CAGTGATCCC 1358
ATATGCTATG AGTTACTGTG GGGTCCAAGG GCACTCGCTG CTTGAAAGTA 1408
CTGGAGCACG TGGTCAGGGT CAATGCAAGA GTTCTCATTT CCTACCCATC 1458
CCTGCGTGAA GCAGCTTTGA GAGAGGAGGA AGAGGGAGTC TGAGCATGAG 1508
CTGCAGCCAG GGCCACTGCG AGGGGGGCTG GGCCAGTGCA CCTTCCAGGG 1558
CTCCGTCCAG TAGTTTCCCC TGCCTTAATG TGACATGAGG CCCATTCTTC 1608
TCTCTTTGAA GAGAGCAGTC AACATTCTTA GTAGTGGGTT TCTGTTCTAT 1658
TGGATGACTT TGAGATTTGT CTTTGTTTCC TTTTGGAATT GTTCAAATGT 1708
TTCTTTTAAT GGGTGGTTGA ATGAACTTCA GCATTCAAAT TTATGAATGA 1758
CAGTAGTCAC ACATAGTGCT GTTTATATAG TTTAGGAGTA AGAGTCTTGT 1808
TTTTTATTCA GATTGGGAAA TCCATTCCAT TTTGTGAATT GGGACATAGT 1858
TACAGCAGTG GAATAAGTAT TCATTTAGAA ATGTGAATGA GCAGTAAAAC 1908
TGATGACATA AAGAAATTAA AAGATATTTA ATTCTTGCTT ATACTCAGTC 1958
TATTCGGTAA AATTTTTTTT AAAAAATGTG CATACCTGGA TTTCCTTGGC 2008
TTCTTTGAGA ATGTAAGACA AATTAAATCT GAATAAATCA TTCTCCCTGT 2058
TCACTGGCTC ATTTATTCTC TATGCACTGA GCATTTGCTC TGTGGAAGGC 2108
CCTGGGTTAA TAGTGGAGAT GCTAAGGTAA GCCAGACTCA CCCCTACCCA 2158
CAGGGTAGTA AAGTCTAGGA GCAGCAGTCA TATAATTAAG GTGGAGAGAT 2208
GCCCTCTAAG ATGTAGAG 2226

(2) INFORMATION FOR SEQUENCE ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2305 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(ix) FEATURE:

(A) NAME/KEY: MAGE-51 gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50
GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100
TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150
GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200
TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250
TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300
GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350
TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400
CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450
GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500
ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT TTTTAGCTGA 550
GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600
AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644
ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 686
GGC CTT GAC ACC CAA GAA GAG CCC TGG GCC TGG TGG GTG TGC 728
AGG CTG CCA CTA CTG AGG AGC AGG AGG CTG TGT CCT CCT CCT 770
CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 812
GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 854
TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 896
AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 938
CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 980
TGG CTG ACT TGA 992
TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCCGGT CACAAAGGCA 1042
GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1092
CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1142
AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1192
CTCCTATGAT GGCCTGGTGG TTTAATCAGA TCATGCCCAA GACGGGCCTC 1242
CTGATAATCG TCTTGGGCAT GATTGCAATG GAGGGCAAAT GCGTCCCTGA 1292
GGAGAAAATC TGGGAGGAGC TGGGTGTGAT GAAGGTGTAT GTTGGGAGGG 1342
AGCACAGTGT CTGTGGGGAG CCCAGGAAGC TGCTCACCCA AGATTTGGTG 1392
CAGGAAAACT ACCTGGAGTA CCGCAGGTGC CCAGCAGTGA TCCCATATGC 1442
TATGAGTTAC TGTGGGGTCC AAGGGCACTC GCTGCTTGAA AGTACTGGAG 1492
CACGTGGTCA GGGTCAATGC AAGAGTTCTC ATTTCCTACC CATCCCTGCA 1542
TGAAGCAGCT TTGAGAGAGG AGGAAGAGGG AGTCTGAGCA TGAGCTGCAG 1592
CCAGGGCCAC TGCGAGGGGG GCTGGGCCAG TGCACCTTCC AGGGCTCCGT 1642
CCAGTAGTTT CCCCTGCCTT AATGTGACAT GAGGCCCATT CTTCTCTCTT 1692
TGAAGAGAGC AGTCAACATT CTTAGTAGTG GGTTTCTGTT CTATTGGATG 1742
ACTTTGAGAT TTGTCTTTGT TTCCTTTTGG AATTGTTCAA ATGTTCCTTT 1792
TAATGGGTGG TTGAATGAAC TTCAGCATTC AAATTTATGA ATGACAGTAG 1842
TCACACATAG TGCTGTTTAT ATAGTTTAGG AGTAAGAGTC TTGTTTTTTA 1892
TTCAGATTGG GAAATCCATT CCATTTTGTG AATTGGGACA TAGTTACAGC 1942
AGTGGAATAA GTATTCATTT AGAAATGTGA ATGAGCAGTA AAACTGATGA 1992
GATAAAGAAA TTAAAAGATA TTTAATTCTT GCCTTATACT CAGTCTATTC 2042
GGTAAAATTT TTTTTAAAA ATGTGCATAC CTGGATTTCC TTGGCTTCTT 2092
TGAGAATGTA AGACAAATTA AATCTGAATA AATCATTCTC CCTGTTCACT 2142
GGCTCATTTA TTCTCTATGC ACTGAGCATT TGCTCTGTGG AAGGCCCTGG 2192
GTTAATAGTG GAGATGCTAA GGTAAGCCAG ACTCACCCCT ACCCACAGGG 2242
TAGTAAAGTC TAGGAGCAGC AGTCATATAA TTAAGGTGGA GAGATGCCCT 2292
CTAAGATGTA GAG 2305

(2) INFORMATION FOR SEQUENCE ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 225 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: MAGE-6 gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

```
TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT TCC GAT TCC TTG     42
CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA GTG GAC CCC ATC     84
GGC CAC GTG TAC ATC TTT GCC ACC TGC CTG GGC CTC TCC TAC    126
GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG CCC AGG ACA GGC    168
TTC CTG ATA ATC ATC CTG GCC ATA ATC GCA AGA GAG GGC GAC    210
TGT GCC CCT GAG GAG                                        225
```

(2) INFORMATION FOR SEQUENCE ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1947 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-7 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

```
TGAATGGACA ACAAGGGCCC CACACTCCCC AGAACACAAG GGACTCCAGA              50
GAGCCCAGCC TCACCTTCCC TACTGTCAGT CCTGCAGCCT CAGCCTCTGC             100
TGGCCGGCTG TACCCTGAGG TGCCCTCTCA CTTCCTCCTT CAGGTTCTCA             150
GCGGACAGGC CGGCCAGGAG GTCAGAAGCC CCAGGAGGCC CCAGAGGAGC             200
ACCGAAGGAG AAGATCTGTA AGTAGGCCTT TGTTAGGGCC TCCAGGGCGT             250
GGTTCACAAA TGAGGCCCCT CACAAGCTCC TTCTCTCCCC AGATCTGTGG             300
GTTCCTCCCC ATCGCCCAGC TGCTGCCCGC ACTCCAGCCT GCTGCCCTGA             350
CCAGAGTCAT CATGTCTTCT GAGCAGAGGA GTCAGCACTG CAAGCCTGAG             400
GATGCCTTGA GGCCCAAGGA CAGGAGGCTC TGGGCCTGGT GGGTGCGCAG             450
GCTCCCGCCA CCGAGGAGCA CGAGGCTGCC TCCTCCTTCA CTCTGATTGA             500
AGGCACCCTG GAGGAGGTGC CTGCTGCTGG GTCCCCCAGT CCTCCCCTGA             550
GTCTCAGGGT TCCTCCTTTT CCCTGACCAT CAGCAACAAC ACTCTATGGA             600
GCCAATCCAG TGAGGGCACC AGCAGCCGGG AAGAGGAGGG GCCAACCACC             650
TAGACACACC CCGCTCACCT GGCGTCCTTG TTCCA                             685
ATG GGA AGG TGG CTG AGT TGG TTC GCT TCC TGC TGC ACA AGT             727
ATC GAG TCA AGG AGC TGG TCA CAA AGG CAG AAA TGC TGG ACA             769
GTG TCA TCA AAA ATT ACA AGC ACT AGT TTC CTT GTG ATC TAT             811
GGC AAA GCC TCA GAG TGC ATG CAG GTG ATG TTT GGC ATT GAC             853
ATG AAG GAA GTG GAC CCC GCG GCC ACT CCT ACG TCC TTG TCA             895
CCT GCT TGG GCC TCT CCT ACA ATG GCC TGC TGG GTG ATG ATC             937
AGA GCA TGC CCG AGA CCG GCC TTC TGA                                964
TTATGGTCTT GACCATGATC TTAATGGAGG GCCACTGTGC CCCTGAGGAG            1014
GCAATCTGGG AAGCGTTGAG TGTAATGGTG TATGATGGGA TGGAGCAGTT            1064
TCTTTGGGCA GCTGAGGAAG CTGCTCACCC AAGATTGGGT GCAGGAAAAC            1114
TACCTGCAAT ACCGCCAGGT GCCCAGCAGT GATCCCCCGT GCTACCAGTT            1164
CCTGTGGGGT CCAAGGGCCC TCATTGAAAC CAGCTATGTG AAAGTCCTGG            1214
AGTATGCAGC CAGGGTCAGT ACTAAAGAGA GCATTTCCTA CCCATCCCTG            1264
CATGAAGAGG CTTTGGGAGA GGAGGAAGAG GGAGTCTGAG CAGAAGTTGC            1314
AGCCAGGGCC AGTGGGGCAG ATTGGGGGAG GGCCTGGGCA GTGCACGTTC            1364
CACACATCCA CCACCTTCCC TGTCCTGTTA CATGAGGCCC ATTCTTCACT            1414
CTGTGTTTGA AGAGAGCAGT CAATGTTCTC AGTAGCGGGG AGTGTGTTGG            1464
GTGTGAGGGA ATACAAGGTG GACCATCTCT CAGTTCCTGT TCTCTTGGGC            1514
GATTTGGAGG TTTATCTTTG TTTCCTTTTG CAGTCGTTCA AATGTTCCTT            1564
TTAATGGATG GTGTAATGAA CTTCAACATT CATTTCATGT ATGACAGTAG            1614
GCAGACTTAC TGTTTTTTAT ATAGTTAAAA GTAAGTGCAT TGTTTTTTAT            1664
TTATGTAAGA AAATCTATGT TATTTCTTGA ATTGGGACAA CATAACATAG            1714
CAGAGGATTA AGTACCTTTT ATAATGTGAA AGAACAAAGC GGTAAAATGG            1764
GTGAGATAAA GAAATAAAGA AATTAAATTG GCTGGGCACG GTGGCTCACG            1814
CCTGTAATCC CAGCACTTTA GGAGGCAGAG GCACGGGGAT CACGAGGTCA            1864
GGAGATCGAG ACCATTCTGG CTAACACAGT GAAACACCAT CTCTATTAAA            1914
AATACAAAAC TTAGCCGGGC GTGGTGGCGG GTG                              1947
```

(2) INFORMATION FOR SEQUENCE ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1810 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-8 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

```
GAGCTCCAGG AACCAGGCTG TGAGGTCTTG GTCTGAGGCA GTATCTTCAA              50
TCACAGAGCA TAAGAGGCCC AGGCAGTAGT AGCAGTCAAG CTGAGGTGGT             100
GTTTCCCCTG TATGTATACC AGAGGCCCCT CTGGCATCAG AACAGCAGGA             150
ACCCCACAGT TCCTGGCCCT ACCAGCCCTT TTGTCAGTCC TGGAGCCTTG             200
GCCTTTGCCA GGAGGCTGCA CCCTGAGATG CCCTCTCAAT TTCTCCTTCA             250
GGTTCGCAGA GAACAGGCCA GCCAGGAGGT CAGGAGGCCC CAGAGAAGCA             300
CTGAAGAAGA CCTGTAAGTA GACCTTTGTT AGGGCATCCA GGGTGTAGTA             350
CCCAGCTGAG GCCTCTCACA CGCTTCCTCT CTCCCCAGGC CTGTGGGTCT             400
CAATTGCCCA GCTCCGGCCC ACACTCTCCT GCTGCCCTGA CCTGAGTCAT             450
C                                                                 451
ATG CTT CTT GGG CAG AAG AGT CAG CGC TAC AAG GCT GAG GAA            493
GGC CTT CAG GCC CAA GGA GAG GCA CCA GGG CTT ATG GAT GTG            535
CAG ATT CCC ACA GCT GAG GAG CAG AAG GCT GCA TCC TCC TCC            577
TCT ACT CTG ATC ATG GGA ACC CTT GAG GAG GTG ACT GAT TCT            619
GGG TCA CCA AGT CCT CCC CAG AGT CCT GAG GGT GCC TCC TCT            661
TCC CTG ACT GTC ACC GAC AGC ACT CTG TGG AGC CAA TCC GAT            703
GAG GGT TCC AGC AGC AAT GAA GAG GAG GGG CCA AGC ACC TCC            745
CCG GAC CCA GCT CAC CTG GAG TCC CTG TTC CGG GAA GCA CTT            787
GAT GAG AAA GTG GCT GAG TTA GTT CGT TTC CTG CTC CGC AAA            829
TAT CAA ATT AAG GAG CCG GTC ACA AAG GCA GAA ATG CTT GAG            871
AGT GTC ATC AAA AAT TAC AAG AAC CAC TTT CCT GAT ATC TTC            913
AGC AAA GCC TCT GAG TGC ATG CAG GTG ATC TTT GGC ATT GAT            955
GTG AAG GAA GTG GAC CCT GCC GGC CAC TCC TAC ATC CTT GTC            997
ACC TGC CTG GGC CTC TCC TAT GAT GGC CTG CTG GGT GAT GAT           1039
CAG AGT ACG CCC AAG ACC GGC CTC CTG ATA ATC GTC CTG GGC           1081
ATG ATC TTA ATG GAG GGC AGC CGC GCC CCG GAG GAG GCA ATC           1123
TGG GAA GCA TTG AGT GTG ATG GGG GCT GTA TGA                       1156
TGGGAGGGAG CACAGTGTCT ATTGGAAGCT CAGGAAGCTG CTCACCCAAG            1206
AGTGGGTGCA GGAGAACTAC CTGGAGTACC GCCAGGCGCC CGGCAGTGAT            1256
CCTGTGCGCT ACGAGTTCCT GTGGGGTCCA AGGGCCCTTG CTGAAACCAG           1306
CTATGTGAAA GTCCTGGAGC ATGTGGTCAG GGTCAATGCA AGAGTTCGCA           1356
TTTCCTACCC ATCCCTGCAT GAAGAGGCTT TGGGAGAGGA GAAAGGAGTT           1406
TGAGCAGGAG TTGCAGCTAG GGCCAGTGGG GCAGGTTGTG GGAGGGCCTG           1456
GGCCAGTGCA CGTTCCAGGG CCACATCCAC CACTTTCCCT GCTCTGTTAC           1506
ATGAGGCCCA TTCTTCACTC TGTGTTTGAA GAGAGCAGTC ACAGTTCTCA           1556
GTAGTGGGGA GCATGTTGGG TGTGAGGGAA CACAGTGTGG ACCATCTCTC           1606
AGTTCCTGTT CTATTGGGCG ATTTGGAGGT TTATCTTTGT TTCCTTTTGG           1656
AATTGTTCCA ATGTTCCTTC TAATGGATGG TGTAATGAAC TTCAACATTC           1706
ATTTTATGTA TGACAGTAGA CAGACTTACT GCTTTTTATA TAGTTTAGGA           1756
GTAAGAGTCT TGCTTTTCAT TTATACTGGG AAACCCATGT TATTTCTTGA           1806
ATTC                                                            1810
```

(2) INFORMATION FOR SEQUENCE ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1412 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-9 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

```
TCTGAGACAG TGTCCTCAGG TCGCAGAGCA GAGGAGACCC AGGCAGTGTC              50
AGCAGTGAAG GTGAAGTGTT CACCCTGAAT GTGCACCAAG GGCCCCACCT             100
GCCCCAGCAC ACATGGGACC CCATAGCACC TGGCCCCATT CCCCCTACTG             150
TCACTCATAG AGCCTTGATC TCTGCAGGCT AGCTGCACGC TGAGTAGCCC             200
TCTCACTTCC TCCCTCAGGT TCTCGGGACA GGCTAACCAG GAGGACAGGA             250
GCCCCAAGAG GCCCCAGAGC AGCACTGACG AAGACCTGTA AGTCAGCCTT             300
TGTTAGAACC TCCAAGGTTC GGTTCTCAGC TGAAGTCTCT CACACACTCC             350
CTCTCTCCCC AGGCCTGTGG GTCTCCATCG CCCAGCTCCT GCCCACGCTC             400
CTGACTGCTG CCCTGACCAG AGTCATC                                      427
ATG TCT CTC GAG CAG AGG AGT CCG CAC TGC AAG CCT GAT GAA             469
GAC CTT GAA GCC CAA GGA GAG GAC TTG GGC CTG ATG GGT GCA             511
CAG GAA CCC ACA GGC GAG GAG GAG GAG ACT ACC TCC TCC TCT             553
GAC AGC AAG GAG GAG GAG GTG TCT GCT GCT GGG TCA TCA AGT             595
CCT CCC CAG AGT CCT CAG GGA GGC GCT TCC TCC TCC ATT TCC             637
GTC TAC TAC ACT TTA TGG AGC CAA TTC GAT GAG GGC TCC AGC             679
AGT CAA GAA GAG GAA GAG CCA AGC TCC TCG GTC GAC CCA GCT             721
CAG CTG GAG TTC ATG TTC CAA GAA GCA CTG AAA TTG AAG GTG             763
GCT GAG TTG GTT CAT TTC CTG CTC CAC AAA TAT CGA GTC AAG             805
GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGC GTC ATC AAA             847
AAT TAC AAG CGC TAC TTT CCT GTG ATC TTC GGC AAA GCC TCC             889
GAG TTC ATG CAG GTG ATC TTT GGC ACT GAT GTG AAG GAG GTG             931
GAC CCC GCC GGC CAC TCC TAC ATC CTT GTC ACT GCT CTT GGC             973
CTC TCG TGC GAT AGC ATG CTG GGT GAT GGT CAT AGC ATG CCC            1015
AAG GCC GCC CTC CTG ATC ATT GTC CTG GGT GTG ATC CTA ACC            1057
AAA GAC AAC TGC GCC CCT GAA GAG GTT ATC TGG GAA GCG TTG            1099
AGT GTG ATG GGG GTG TAT GTT GGG AAG GAG CAC ATG TTC TAC            1141
GGG GAG CCC AGG AAG CTG CTC ACC CAA GAT TGG GTG CAG GAA            1183
AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT GCG            1225
CAC TAC GAG TTC CTG TGG GGT TCC AAG GCC CAC GCT GAA ACC            1267
AGC TAT GAG AAG GTC ATA AAT TAT TTG GTC ATG CTC AAT GCA            1309
AGA GAG CCC ATC TGC TAC CCA TCC CTT TAT GAA GAG GTT TTG            1351
GGA GAG GAG CAA GAG GGA GTC TGA                                   1375
GCACCAGCCG CAGCCGGGGC CAAAGTTTGT GGGGTCA                          1412
```

(2) INFORMATION FOR SEQUENCE ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 920 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-10 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

```
ACCTGCTCCA GGACAAAGTG GACCCCACTG CATCAGCTCC ACCTACCCTA              50
CTGTCAGTCC TGGAGCCTTG GCCTCTGCCG GCTGCATCCT GAGGAGCCAT             100
CTCTCACTTC CTTCTTCAGG TTCTCAGGGG ACAGGGAGAG CAAGAGGTCA             150
AGAGCTGTGG GACACCACAG AGCAGCACTG AAGGAGAAGA CCTGTAAGTT             200
GGCCTTTGTT AGAACCTCCA GGGTGTGGTT CTCAGCTGTG GCCACTTACA             250
CCCTCCCTCT CTCCCCAGGC CTGTGGGTCC CCATCGCCCA AGTCCTGCCC             300
ACACTCCCAC CTGCTACCCT GATCAGAGTC ATC                               333
ATG CCT CGA GCT CCA AAG CGT CAG CGC TGC ATG CCT GAA GAA             375
GAT CTT CAA TCC CAA AGT GAG ACA CAG GGC CTC GAG GGT GCA             417
CAG GCT CCC CTG GCT GTG GAG GAG GAT GCT TCA TCA TCC ACT             459
TCC ACC AGC TCC TCT TTT CCA TCC TCT TTT CCC TCC TCC TCC             501
TCT TCC TCC TCC TCC TCC TGC TAT CCT CTA ATA CCA AGC ACC             543
CCA GAG GAG GTT TCT GCT GAT GAT GAG ACA CCA AAT CCT CCC             585
CAG AGT GCT CAG ATA GCC TGC TCC TCC CCC TCG GTC GTT GCT             627
TCC CTT CCA TTA GAT CAA TCT GAT GAG GGC TCC AGC AGC CAA             669
AAG GAG GAG AGT CCA AGC ACC CTA CAG GTC CTG CCA GAC AGT             711
GAG TCT TTA CCC AGA AGT GAG ATA GAT GAA AAG GTG ACT GAT             753
TTG GTG CAG TTT CTG CTC TTC AAG TAT CAA ATG AAG GAG CCG             795
ATC ACA AAG GCA GAA ATA CTG GAG AGT GTC ATA AAA AAT TAT             837
GAA GAC CAC TTC CCT TTG TTG TTT AGT GAA GCC TCC GAG TGC             879
ATG CTG CTG GTC TTT GGC ATT GAT GTA AAG GAA GTG GAT CC              920
```

(2) INFORMATION FOR SEQUENCE ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1107 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: MAGE-11 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

AGAGAACAGG CCAACCTGGA GGACAGGAGT CCCAGGAGAA CCCAGAGGAT 50
CACTGGAGGA GAACAAGTGT AAGTAGGCCT TTGTTAGATT CTCCATGGTT 100
CATATCTCAT CTGAGTCTGT TCTCACGCTC CCTCTCTCCC CAGGCTGTGG 150
GGCCCCATCA CCCAGATATT TCCCACAGTT CGGCCTGCTG ACCTAACCAG 200
AGTCATCATG CCTCTTGAGC AAAGAAGTCA GCACTGCAAG CCTGAGGAAG 250
CCTTCAGGCC CAAGAAGAAG ACCTGGGCCT GGTGGGTGCA CAGGCTCTCC 300
AAGCTGAGGA GCAGGAGGCT GCCTTCTTCT CCTCTACTCT GAATGTGGGC 350
ACTCTAGAGG AGTTGCCTGC TGCTGAGTCA CCAAGTCCTC CCCAGAGTCC 400
TCAGGAAGAG TCCTTCTCTC CCACTGCCAT GGATGCCATC TTTGGGAGCC 450
TATCTGATGA GGGCTCTGGC AGCCAAGAAA AGGAGGGGCC AAGTACCTCG 500
CCTGACCTGA TAGACCCTGA GTCCTTTTCC CAAGATATAC TACATGACAA 550
GATAATTGAT TTGGTTCATT TATTCTCCGC AAGTATCGAG TCAAGGGGCT 600
GATCACAAAG GCAGAA 616
ATG CTG GGG AGT GTC ATC AAA AAT TAT GAG GAC TAC TTT CCT 658
GAG ATA TTT AGG GAA GCC TCT GTA TGC ATG CAA CTG CTC TTT 700
GGC ATT GAT GTG AAG GAA GTG GAC CCC ACT AGC CAC TCC TAT 742
GTC CTT GTC ACC TCC CTC AAC CTC TCT TAT GAT GGC ATA CAG 784
TGT AAT GAG CAG AGC ATG CCC AAG TCT GGC CTC CTG ATA ATA 826
GTC CTG GGT GTA ATC TTC ATG GAG GGG AAC TGC ATC CCT GAA 868
GAG GTT ATG TGG GAA GTC CTG AGC ATT ATG GGG GTG TAT GCT 910
GGA AGG GAG CAC TTC CTC TTT GGG GAG CCC AAG AGG CTC CTT 952
ACC CAA AAT TGG GTG CAG GAA AAG TAC CTG GTG TAC CGG CAG 994
GTG CCC GGC ACT GAT CCT GCA TGC TAT GAG TTC CTG TGG GGT 1036
CCA AGG GCC CAC GCT GAG ACC AGC AAG ATG AAA GTT CTT GAG 1078
TAC ATA GCC AAT GCC AAT GGG AGG GAT CC 1107

(2) INFORMATION FOR SEQUENCE ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2150 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: smage-I
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

```
TCTGTCTGCA TATGCCTCCA CTTGTGTGTA GCAGTCTCAA ATGGATCTCT              50
CTCTACAGAC CTCTGTCTGT GTCTGGCACC CTAAGTGGCT TTGCATGGGC             100
ACAGGTTTCT GCCCCTGCAT GGAGCTTAAA TAGATCTTTC TCCACAGGCC             150
TATACCCCTG CATTGTAAGT TTAAGTGGCT TTATGTGGAT ACAGGTCTCT             200
GCCCTTGTAT GCAGGCCTAA GTTTTTCTGT CTGCTTAACC CCTCCAAGTG             250
AAGCTAGTGA AAGATCTAAC CCACTTTTGG AAGTCTGAAA CTAGACTTTT             300
ATGCAGTGGC CTAACAAGTT TTAATTTCTT CCACAGGGTT TGCAGAAAAG             350
AGCTTGATCC ACGAGTTCAG AAGTCCTGGT ATGTTCCTAG AAAG                   394
ATG TTC TCC TGG AAA GCT TCA AAA GCC AGG TCT CCA TTA AGT             436
CCA AGG TAT TCT CTA CCT GGT AGT ACA GAG GTA CTT ACA GGT             478
TGT CAT TCT TAT CCT TCC AGA TTC CTG TCT GCC AGC TCT TTT             520
ACT TCA GCC CTG AGC ACA GTC AAC ATG CCT AGG GGT CAA AAG             565
AGT AAG ACC CGC TCC CGT GCA AAA CGA CAG CAG TCA CGC AGG             604
GAG GTT CCA GTA GTT CAG CCC ACT GCA GAG GAA GCA GGG TCT             646
TCT CCT GTT GAC CAG AGT GCT GGG TCC AGC TTC CCT GGT GGT             688
TCT GCT CCT CAG GGT GTG AAA ACC CCT GGA TCT TTT GGT GCA             730
GGT GTA TCC TGC ACA GGC TCT GGT ATA GGT GGT AGA AAT GCT             772
GCT GTC CTG CCT GAT ACA AAA AGT TCA GAT GGC ACC CAG GCA             814
GGG ACT TCC ATT CAG CAC ACA CTG AAA GAT CCT ATC ATG AGG             856
AAG GCT AGT GTG CTG ATA GAA TTC CTG CTA GAT AAA TTT AAG             898
ATG AAA GAA GCA GTT ACA AGG AGT GAA ATG CTG GCA GTA GTT             940
AAC AAG AAG TAT AAG GAG CAA TTC CCT GAG ATC CTC AGG AGA             982
ACT TCT GCA CGC CTA GAA TTA GTC TTT GGT CTT GAG TTG AAG            1024
GAA ATT GAT CCC AGC ACT CAT TCC TAT TTG CTG GTA GGC AAA            1066
CTG GGT CTT TCC ACT GAG GGA AGT TTG AGT AGT AAC TGG GGG            1108
TTG CCT AGG ACA GGT CTC CTA ATG TCT GTC CTA GGT GTG ATC            1150
TTC ATG AAG GGT AAC CGT GCC ACT GAG CAA GAG GTC TGG CAA            1192
TTT CTG CAT GGA GTG GGG GTA TAT GCT GGG AAG AAG CAC TTG            1234
ATC TTT GGC GAG CCT GAG GAG TTT ATA AGA GAT GTA GTG CGG            1276
GAA AAT TAC CTG GAG TAC CGC CAG GTA CCT GGC AGT GAT CCC            1314
CCA AGC TAT GAG TTC CTG TGG GGA CCC AGA GCC CAT GCT GAA            1360
ACA ACC AAG ATG AAA GTC CTG GAA GTT TTA GCT AAA GTC AAT            1402
GGC ACA GTC CCT AGT GCC TTC CCT AAT CTC TAC CAG TTG GCT            1444
CTT AGA GAT CAG GCA GGA GGG GTG CCA AGA AGG AGA GTT CAA            1486
GGC AAG GGT GTT CAT TCC AAG GCC CCA TCC CAA AAG TCC TCT            1528
AAC ATG TAG                                                       1537
TTGAGTCTGT TCTGTTGTGT TTGAAAAACA GTCAGGCTCC TAATCAGTAG             1587
AGAGTTCATA GCCTACCAGA ACCAACATGC ATCCATTCTT GGCCTGTTAT             1637
ACATTAGTAG AATGGAGGCT ATTTTTGTTA CTTTTCAAAT GTTTGTTTAA             1687
CTAAACAGTG CTTTTTGCCA TGCTTCTTGT TAACTGCATA AAGAGGTAAC             1737
TGTCACTTGT CAGATTAGGA CTTGTTTTGT TATTTGCAAC AAACTGGAAA             1787
ACATTATTTT GTTTTTACTA AAACATTGTG TAACATTGCA TTGGAGAAGG             1837
GATTGTCATG GCAATGTGAT ATCATACAGT GGTGAAACAA CAGTGAAGTG             1887
GGAAAGTTTA TATTGTTAAT TTTGAAAATT TTATGAGTGT GATTGCTGTA             1937
TACTTTTTTC TTTTTTGTAT AATGCTAAGT GAAATAAAGT TGGATTTGAT             1987
GACTTTACTC AAATTCATTA GAAAGTAAAT CGTAAAACTC TATTACTTTA             2037
TTATTTTCTT CAATTATGAA TTAAGCATTG GTTATCTGGA AGTTTCTCCA             2087
GTAGCACAGG ATCTAGTATG AAATGTATCT AGTATAGGCA CTGACAGTGA             2137
GTTATCAGAG TCT                                                    2150
```

(2) INFORMATION FOR SEQUENCE ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2099 base pairs
(B) TYPE: nucleic acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(ix) FEATURE:
(A) NAME/KEY: smage-II
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

ACCTTATTGG GTCTGTCTGC ATATGCCTCC ACTTGTGTGT AGCAGTCTCA 50
AATGGATCTC TCTCTACAGA CCTCTGTCTG TGTCTGGCAC CCTAAGTGGC 100
TTTGCATGGG CACAGGTTTC TGCCCCTGCA TGGAGCTTAA ATAGATCTTT 150
CTCCACAGGC CTATACCCCT GCATTGTAAG TTTAAGTGGC TTTATGTGGA 200
TACAGGTCTC TGCCCTTGTA TGCAGGCCTA AGTTTTTCTG TCTGCTTAGC 250
CCCTCCAAGT GAAGCTAGTG AAAGATCTAA CCCACTTTTG GAAGTCTGAA 300
ACTAGACTTT TATGCAGTGG CCTAACAAGT TTTAATTTCT TCCACAGGGT 350
TTGCAGAAAA GAGCTTGATC CACGAGTTCG GAAGTCCTGG TATGTTCCTA 400
GAAAGATGTT CTCCTGGAAA GCTTCAAAAG CCAGGTCTCC ATTAAGTCCA 450
AGGTATTCTC TACCTGGTAG TACAGAGGTA CTTACAGGTT GTCATTCTTA 500
TCTTTCCAGA TTCCTGTCTG CCAGCTCTTT TACTTCAGCC CTGAGCACAG 550
TCAACATGCC TAGGGGTCAA AAGAGTAAGA CCCGCTCCCG TGCAAAACGA 600
CAGCAGTCAC GCAGGGAGGT TCCAGTAGTT CAGCCCACTG CAGAGGAAGC 650
AGGGTCTTCT CCTGTTGACC AGAGTGCTGG GTCCAGCTTC CCTGGTGGTT 700
CTGCTCCTCA GGGTGTGAAA ACCCCTGGAT CTTTTGGTGC AGGTGTATCC 750
TGCACAGGCT CTGGTATAGG TGGTAGAAAT GCTGCTGTCC TGCCTGATAC 800
AAAAAGTTCA GATGGCACCC AGGCAGGGAC TTCCATTCAG CACACACTGA 850
AAGATCCTAT CATGAGGAAG GCTAGTGTGC TGATAGAATT CCTGCTAGAT 900
AAGTTTAAGA TGAAAGAAGC AGTTACAAGG AGTGAAATGC TGGCAGTAGT 950
TAACAAGAAG TATAAGGAGC AATTCCCTGA GATCCTCAGG AGAACTTCTG 1000
CACGCCTAGA ATTAGTCTTT GGTCTTGAGT TGAAGGAAAT TGATCCCAGC 1050
ACTCATTCCT ATTTGCTGGT AGGCAAACTG GGTCTTTCCA CTGAGGGAAG 1100
TTTGAGTAGT AACTGGGGGT TGCCTAGGAC AGGTCTCCTA ATGTCTGTCC 1150
TAGGTGTGAT CTTCATGAAG GGTAACCGTG CCACTGAGCA AGAGGTCTGG 1200
CAATTTCTGC ATGGAGTGGG GGTATATGCT GGGAAGAAGC ACTTGATCTT 1250
TGGCGAGCCT GAGGAGTTTA TAAGAGATGT AGTGCGGGAA AATTACCTGG 1300
AGTACCGCCA GGTACCTGGC AGTGATCCCC CAAGCTATGA GTTCCTGTGG 1350
GGACCCAGAG CCCATGCTGA AACAACCAAG ATGAAAGTCC TGGAAGTTTT 1400
AGCTAAAGTC AATGGCACAG TCCCTAGTGC CTTCCCTAAT CTCTACCAGT 1450
TGGCTCTTAG AGATCAGGCA GGAGGGGTGC CAAGAAGGAG AGTTCAAGGC 1500
AAGGGTGTTC ATTCCAAGGC CCCATCCCAA AAGTCCTCTA ACATGTAGTT 1550
GAGTCTGTTC TGTTGTGTTT GAAAAACAGT CAGGCTCCTA ATCAGTAGAG 1600
AGTTCATAGC CTACCAGAAC CAACATGCAT CCATTCTTGG CCTGTTATAC 1650
ATTAGTAGAA TGGAGGCTAT TTTTGTTACT TTTCAAATGT TTGTTTAACT 1700
AAACAGTGCT TTTTGCCATG CTTCTTGTTA ACTGCATAAA GAGGTAACTG 1750
TCACTTGTCA GATTAGGACT TGTTTTGTTA TTTGCAACAA ACTGGAAAAC 1800
ATTATTTTGT TTTTACTAAA ACATTGTGTA ACATTGCATT GGAGAAGGGA 1850
TTGTCATGGC AATGTGATAT CATACAGTGG TGAAACAACA GTGAAGTGGG 1900
AAAGTTTATA TTGTTAGTTT TGAAAATTTT ATGAGTGTGA TTGCTGTATA 1950
CTTTTTTCTT TTTTGTATAA TGCTAAGTGA AATAAAGTTG GATTTGATGA 2000
CTTTACTCAA ATTCATTAGA AAGTAAATCA TAAAACTCTA TTACTTTATT 2050
ATTTTCTTCA ATTATTAATT AAGCATTGGT TATCTGGAAG TTTCTCCAG 2099

(2) INFORMATION FOR SEQUENCE ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acids
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Glu Ala Asp Pro Thr Gly His Ser Tyr
5

We claim:

1. Isolated nucleic acid molecule which codes for or is complementary to a nucleic acid molecule which codes for tumor rejection antigen precursor MAGE-3.

2. The isolated nucleic acid molecule of claim 1, which codes for tumor rejection antigen precursor MAGE-3.

3. The nucleic acid molecule of claim 2, wherein said molecule is cDNA.

4. The nucleic acid molecule of claim 3, wherein said molecule has the nucleotide sequence set forth in SEQ ID NO: 1 (MAGE-3) or SEQ ID NO: 2 (MAGE-31).

5. Expression vector comprising the nucleic acid molecule of claim 2 operably linked to a promoter.

6. The expression vector of claim 5, further comprising a nucleic acid molecule which codes for HLA-A1.

7. Cell line transfected with the nucleic acid molecule of claim 2.

8. The cell line of claim 7, wherein said cell line expresses HLA-A1.

9. The cell line of claim 7, wherein said cell line is further transfected with a nucleic acid molecule which codes for HLA-A1.

10. Isolated tumor rejections antigen precursor coded for by the nucleic acid molecule of claim 2.

11. Vaccine comprising the isolated tumor rejection antigen precursor of claim 10 and an adjuvant.

12. Isolated tumor rejection antigen derived from the tumor rejection antigen precursor of claim 10, wherein said tumor rejection antigen is antigen D.

13. Isolated complex of the tumor rejection antigen of claim 12 and HLA-A1.

14. Method for treating a disorder characterized by expression of tumor rejection antigen precursor MAGE-3, comprising administering to a subject an amount of a cytolytic T cell specific for complexes of a tumor rejection antigen derived from MAGE-3 and a human leukocyte antigen molecule, sufficient to generate an immune response against said complexes.

15. The method of claim 14, wherein said human leukocyte antigen is HLA-A1.

16. The method of claim 15, wherein said tumor rejection antigen is antigen D.

17. Method for treating a disorder characterized by expression of tumor rejection antigen precursor MAGE-3, comprising administering an agent sufficient to provoke an immune response to complexes of a tumor rejection antigen derived from MAGE-3 and a human leukocyte antigen, to a subject in need thereof.

18. The method of claim 17, wherein said human leukocyte antigen is HLA-A1.

19. The method of claim 18, wherein said tumor rejection antigen is antigen D.

20. Method for determining a disorder characterized by expression of tumor rejection antigen precursor MAGE-3, comprising contacting a sample taken from a subject with an agent which identifies said tumor rejection antigen

precursor to determine expression of said tumor rejection antigen precursor as a determination of said disorder.

21. Method for determining a disorder characterized by expression of tumor rejection antigen precursor MAGE-3 and presentation of a tumor rejection antigen derived therefrom by a cell, comprising contacting a sample taken with a subject with an agent which identifies said tumor rejection antigen to determine said tumor rejection antigen as a determination of said disorder.

ABSTRACT OF THE DISCLOSURE

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.

FIG. 1A


% SPECIFIC LYSIS
70
60
50
40
30
20
10
P0.HTR – – 44,000 44,000
P0.HTR – 1,500 1,500 –

FIG. 1B



FIG. 2


CTL
anti-A
anti-B
anti-C
anti-D
TARGETS
P1.HTR
P0.HTR
P1A.T2
P1A.TD3.1
% SPECIFIC LYSIS
0
20
40
60
80
.1
.3
1
3
10
EFFECTOR / TARGET RATIO

FIG. 3



FIG. 4


1
2
3
4
5
6
7
P1.HTR
P1.HTR
PO.HTR
L138.8A
P1.HTR
Liver DBA/2
Spleen DBA/2
P1A probe a
P1A probe b
kb
2.6
1.5
1.2
ß-actin probe

FIG. 5



FIG. 6


CTL
anti-P815A
CTL
anti-P815B
TARGETS
PO.HTR
+P815
gene
PO.HTR
+gene of
kidney cells
PO.HTR
% SPECIFIC LYSIS
40
20
0
40
20
0
20
0
.1
.3
1
3
.1
.3
1
3
EFFECTOR / TARGET RATIO

FIG. 7


CTL
anti-A
anti-B
anti-C
anti-D
TARGETS
P1.HTR
L138.8A
% SPECIFIC LYSIS
80
60
40
20
0
.1 .3 1 3 10
EFFECTOR / TARGET RATIO


Sma I
Bam HI
0
1
2
3
4
5 kb
24kb
912
215
255

FIG. 8

FIG. 9

```
MAGE-3 III CCTCCCCAGAGTCCTCAGGGAGCCTCCagCcTcCCCACTACCATgAACTaCcCTCtctgGAGcCAAtCCtaTGAGGacTCCAGCAaCCaaGAAGAGGAGG
                                                                                   <--------------------CHO-3
MAGE-2 II  CCTCCCCAcAGTCCTCAGGGAGCCTCCagCTTctCgACTACCATCAACTaCACTCtttgGAGaCAAtCCgaTGAGGGcTCCAGCAaCCaaGAAGAGGAGG
                                                                                   <--------------------CHO-2
MAGE-1 I   CCTCCCCAGAGTCCTCAGGGAGCCTCCGCCTTTCCCACTACCATCAACTTCACTCGACAGAGGCAACCCAGTGAGGGTTCCAGCAGCCGTGAAGAGGAGG
       225  CHO-8 ------------>

       III GGCCAAGCACCTtcccTgaCC-TGGAGTCCgaGTTCCaAGCAGcAcTCAgTAgGAAGGTGGCcGAgTTGGTTcaTTTTCTGCTCCTCAAgTATCGAGCCA
       II  GGCCAAGaAtgTtTcccgaCCtTGGAGTCCGAGTTCCaAGCAGcAATCAgTAgGAAGaTGGtTGAgTTGGTTcaTTTTCTGCTCCTCAAgTATCGAGCCA
       I   GGCCAAGCACCTCTTGTATCC-TGGAGTCCTTGTTCCGAGCAGTAATCACTAAGAAGGTGGCTGATTTGGTTGGTTTTCTGCTCCTCAAATATCGAGCCA
       325

       III GGGAGCCgGTCACAAAGGCAGAAATGCTGGgGAGTGTCgTCggAAATTggcAGtAtTtcTTTCCTGtGATCTTCaGCAAAGCtTCcagtTCCTTGCAGCT
       II  GGGAGCCgGTCACAAAGGCAGAAATGCTGGAGAGTGTCcTCAgAAATTgCcAGgACTtcTTTCCCgtGATCTTCaGCAAAGCCTCcGAGTaCTTGCAGCT
       I   GGGAGCCAGTCACAAAGGCAGAAATGCTGGAGAGTGTCATCAAAAATTACAAGCACTGTTTTCCTGAGATCTTCGGCAAAGCCTCTGAGTCCTTGCAGCT
       425                                                                <--------------------SEQ-4

       III GGTCTTTGGCATcGAgcTGAtGGAAGtgGACCCCAtCGGCCACTtgTAcaTCtTTGcCACCTGCCTgGGcCTCTCCTAcGATGGCCTGCTGGGTGAcAAT
       II  GGTCTTTGGCATcGAgGTGgtGGAAGtgGtCCCCAtCaGCCACTtgTAcaTCCTTGTCACCTGCCTgGGcCTCTCCTAcGATGGCCTGCTGGGcGAcAAT
       I   GGTCTTTGGCATTGACGTGAAGGAAGCAGACCCCACCGGCCACTCCTATGTCCTTGTCACCTGCCTAGGTCTCTCCTATGATGGCCTGCTGGGTGATAAT
       525

       III CAGATCATGCCCAAGgCAGGCcTCCTGATAATcGTCCTGGcCATaATcGCAAgaGAGGGCGaCtgTGCcCCTGAGGAGaAAATCTGGGAGGAGCTGAGTG
       II  CAGgTCATGCCCAAGACAGGCcTCCTGATAATcGTC-TGGcCATaATcGCAATaGAGGGCGaCtgTGCcCCTGAGGAGaAAATCTGGGAGGAGCTGAGTa
       I   CAGATCATGCCCAAGACAGGCTTCCTGATAATTGTCCTGGTCATGATTGCAATGGAGGGCGGCCATGCTCCTGAGGAGGAAATCTGGGAGGAGCTGAGTG
       625                                                                                <--------------------CHO-9
```


β–action
MAGE
PROBES
MZ2-MEL.3.0
MZ2-MEL 1982
MZ2-MEL.2.2 E-
MZ2-PBL-PHA
Lung
Kidney
MZ2-MEL 3.0
MZ2-CTL 82/30
LB34-MEL
LB17-MEL
MI665/2-MEL
LB41-MEL
MI10221-MEL
MI13443-MEL
SK23-MEL
SK33-MEL
LB4-MEL
MI4024-MEL
MZ3-MEL
MZ5-MEL
SK29-MEL
LB31-COL
LS411-COL
H209-SCLC
H345-SCLC
H510-SCLC
TT
Other melanomas
Other tumors

FIG. 10

FIG. 11

		EXPRSSION OF MAGE GENE FAMILY				RECOGNITIN BY ANI-E CTL		Expression of antigen MZ2-E after transaction**
		Northern blot probed with cross-reactive MAGE-1 probe*	cDNA-PCR product probed with oligonucleotide specific for:			tested by:		
			MAGE-1	MAGE-2	MAGE-3†	TNF release‡	Lysis§	
Cells of patient MZ2	melanoma cell line MZ2-MEL.3.0	+	+++	++++	++++	+	+	
	tumor sample MZ2 (1982)	+	+++	+++	+++			
	antigen-loss variant MZ2-MEL.2.2	+	–	+++	+++	–	–	
	CTL clone MZ2-CTL.82/30	–	–	–	–			
	PHA-activated blood lymphocytes	–	–	–	–			
Normal tissues	Liver	–	–	–	–			
	Muscle	–	–	–	–			
	Skin	–	–	–	–			
	Lung	–	–	–	–			
	Brain	–	–	–	–			
	Kidney	–	–	–	–			
Melanoma cell lines of HLA-A1 patients	LB34-MEL	+	++	++++	++++	+	+–	
	M665/2-MEL	–	–	–	–	–	–	+
	M10221-MEL	+	–	++	+++	–	–	+
	M13443-MEL	+	+++	++++	++++	+	+	
	SK33-MEL	+	–	++++	++++	–	–	–
	SK23-MEL	+	–	++++	++++	–	–	+
Melanoma cell lines of other patients	LB17-MEL	+	+	++++	++++	–	–	–
	LB33-MEL	+	–	+++	+++	–	–	–
	LB4-MEL	–	–	–	–	–	–	
	LB41-MEL	–	–	–	–	–	–	
	M4024-MEL	+	+++	++++	++++	–	–	
	SK29-MEL	–	–	–	–	–	–	
	MZ3-MEL	+	+	++++	++++	–	–	
	MZ5-MEL	+	–	++++	++++	–	–	
Melanoma tumor sample	B85-MEL	+	+++	++	+++			
Other tumor cell lines	small cell lung cancer H209	+	–	++++	++++			
	small cell lung cancer H345	+	–	++++	++++			
	small cell lung cancer H510	+	–	++++	++++			
	small cell lung cancer LB11	+	+	++++	++++			
	bronchial squamous cell carcinoma LB37	+	–	–	+++			
	thyroid medullary carcinoma TT	+	++++	+++	++++			
	colon carcinoma LB31	+	–	+++	++++	–		
	colon carcinoma LS411	–	–	–	–			
Other tumor samples	chronic myeloid leukemia LLC5	–	–	–	–			
	acute myeloid leukemia TA	–	–	–	–			

* Data obtained in the conditions of figure 5.
† Data obtained as described in figure 6.
‡ TNF release by CTL 82/30 after stimulation with the tumor cells as described in (11).
§ Lysis of 51 Cr labeled target by CTL 82/30 in the conditions of figure 1.
** Cells transfected with the 2.4 kb fragment of gene MAGE-1 were tested for their ability to stimulate TNF release by CTL 82/30

FIG. 12



FIG. 13




MZ2-CTL-22/18
MZ2-CTL-25/38
% SPECIFIC ^{51}Cr RELEASE
70
60
50
40
30
20
10
0
0.1
1
10
0.3
3
EFFECTOR / TARGET RATIO
TARGETS
MZ2-MEL.3.0
MZ2-EBV
MZ2-FIBROBLASTS
SK-MEL-29
K562

Fig. 14


CTL anti-A' (26/335)
CTL anti-F (76/6)
CTL anti-E (22/13)
CTL anti-D (20/38)
TARGETS
MZ2-MEL.6.0 A+ (D+ E+ F+ A'+)
MZ2-MEL.61 D-
MZ2-MEL.2.2 E-
MZ2-MEL.4 F-
% SPECIFIC ⁵¹Cr RELEASE
EFFECTOR / TARGET RATIO

Fig. 15


TNF released by CTL assay (pg/ml)
>180
>180
4
8
9
7
MZ1-MEL.81.2
MZ1-MEL-ET1
COS+HLA-A1
COS+HLA-A1
COS+HLA-A1
COS+HLA-A1

Fig. 16

LUD 253.5-JEL/NDH

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR MAGE-3 AND USES THEREOF, the specification of which

( ) is attached hereto.
(X) was filed on March 26, 1993 as Application Serial No. 08/037,230 and was amended on (1) _____, (2) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

(Number)	(Country)	(Day/Month/Year Filed)	Priority Claimed Yes ( ) No ( )

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
PCT/US92/04354	May 22, 1992	Pending
07/807,043	December 12, 1991	Pending

07/764,364	September 23, 1991	Pending
(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
07/728,838	July 9, 1991	Pending
(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
07/705,702	May 23, 1991	Pending
(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)

Power of Attorney

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Alfred H. Hemingway, Jr., Reg. No. 26,736; Vincent M. Fazzari, Reg. No. 26,879; Frederick H. Rabin, Reg. No. 24,488; Hallie R. Levie, Reg. No. 31,116; Charles A. Blank, Reg. No. 17,419; Norman D. Hanson, Reg. No. 30,946; Walter G. Weissenberger, Reg. No. 17,344; F. Brice Faller, Reg. No. 29,532; Andrew L. Tiajoloff, Reg. No. 31,575; John P. Luther, Reg. No. 32,261; Christine H. Tsai, Reg. No. 34,266 and John A. Bauer, Reg. No. 32,554, my attorneys with full power of substitution and revocation. Address all telephone calls to Norman D. Hanson, Esq., at (212) 688-9200. Address all correspondence to:

FELFE & LYNCH
805 Third Avenue
New York, New York 10022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Béatrice ~~Guagler~~ au

Full Name/Sole or First Inventor

Signature

7 april 93

Date

Residence: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium

French ~~Belgian~~

Citizenship

Post Office Address: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium

2) Benoit Van den Eynde — Signature — 7 April 93
ull Name/Second Inventor — Signature — Date

esidence: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium — Belgian Citizenship

ost Office Address: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium

) Pierre van ~~den~~ der Bruggen — Signature — 13 April 93
ull Name/Third Inventor — Signature — Date

sidence: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium — Belgian Citizenship

st Office Address: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium

Thierry Boon-Falleur — Signature — 7 avril 93
ll Name/Fourth Inventor — Signature — Date

sidence: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium — Belgian Citizenship

st Office Address: Avenue Hippocrate 74, UCL 7459
1200 Brussels, Belgium

VIA EXPRESS MAIL
"Express Mail" mailing label Number EL227321843US
Date of Deposit May 31, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231
FULBRIGHT & JAWORSKI L.L.P.
By: Joan Cerrone

LUD 5353.7 DIV (10016357)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Boon, et al
Serial No.	:	TO BE ASSIGNED
Filed	:	HEREWITH
For	:	Isolated Nucleic Acid Molecules Coding For Tumor Rejection Antigen Precursor Mage-6 And Uses Thereof
Group Art Unit	:	NOT YET ASSIGNED
Examiner	:	NOT YET ASSIGNED

May 31, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

LETTER RE CHANGE IN ATTORNEYS ADDRESS

Sir:

The USPTO is asked to correct the mailing address in the above referenced applicaiton.

The attorneys of record in this application are:

FULBRIGHT & JAWORSKI LLP

666 Fifth Avenue
New York, New York 10103
Attn: Norman D. Hanson

The telephone number is 212-318-3000, and the facsimile number is 212-318-3400.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By_______________________
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000